U.S. patent application number 12/377446 was filed with the patent office on 2011-01-06 for immunogenic pcpa polypeptides and uses thereof.
This patent application is currently assigned to THE UAB RESEARCH FOUNDATION. Invention is credited to David E. Briles, Susan K. Hollingshead, Joe Wang, Jeremy Yethon.
Application Number | 20110002962 12/377446 |
Document ID | / |
Family ID | 38942273 |
Filed Date | 2011-01-06 |
United States Patent
Application |
20110002962 |
Kind Code |
A1 |
Briles; David E. ; et
al. |
January 6, 2011 |
Immunogenic PcpA Polypeptides and Uses Thereof
Abstract
Provided herein are compositions and methods for eliciting an
immune response against Streptococcus pneumoniae. More
particularly, the compositions and methods relate to immunogenic
polypeptides, including fragments of PcpA and variants thereof, and
nucleic acids, vectors and transfected cells that encode or express
the polypeptides. Methods of making and using the immunogenic
polypeptides are also described.
Inventors: |
Briles; David E.;
(Birmingham, AL) ; Hollingshead; Susan K.;
(Birmingham, AL) ; Yethon; Jeremy; (Toronto,
CA) ; Wang; Joe; (Toronto, CA) |
Correspondence
Address: |
FISH & RICHARDSON P.C. (AT)
P.O BOX 1022
Minneapolis
MN
55440-1022
US
|
Assignee: |
THE UAB RESEARCH FOUNDATION
Birmingham
AL
SANOFI PASTEUR LTD.
Toronto
ON
|
Family ID: |
38942273 |
Appl. No.: |
12/377446 |
Filed: |
August 17, 2007 |
PCT Filed: |
August 17, 2007 |
PCT NO: |
PCT/US07/76180 |
371 Date: |
April 9, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60822715 |
Aug 17, 2006 |
|
|
|
60827348 |
Sep 28, 2006 |
|
|
|
60917178 |
May 10, 2007 |
|
|
|
Current U.S.
Class: |
424/244.1 ;
424/203.1; 530/350 |
Current CPC
Class: |
A61P 27/16 20180101;
A61P 25/00 20180101; A61P 13/12 20180101; A61P 31/04 20180101; G01N
2400/10 20130101; A61P 11/00 20180101; A61P 31/00 20180101; C07K
14/3156 20130101; G01N 33/56944 20130101; A61P 13/00 20180101 |
Class at
Publication: |
424/244.1 ;
530/350; 424/203.1 |
International
Class: |
A61K 39/09 20060101
A61K039/09; C07K 14/195 20060101 C07K014/195; A61K 39/116 20060101
A61K039/116; A61P 31/04 20060101 A61P031/04 |
Goverment Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under Grants
R01 AI053749, R01 A121548 and T32 HL 07553 from the National
Institutes of Health. The government may have certain rights in the
invention.
Claims
1-23. (canceled)
24. An immunogenic fragment of PcpA comprising one or more leucine
rich regions of naturally occurring PcpA.
25. The immunogenic fragment of claim 24, wherein the fragment
lacks a choline binding anchor sequence.
26. The immunogenic fragment of claim 24, wherein the leucine rich
region comprises an N-terminal region of naturally occurring
PcpA.
27. The immunogenic fragment of claim 26, wherein the N-terminal
region comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID
NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID
NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ
ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18,
SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID
NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ
ID NO:28 or SEQ ID NO:41 with one or more conservative amino acid
substitutions.
28. The immunogenic fragment of claim 26, wherein the N-terminal
region comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID
NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID
NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ
ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18,
SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID
NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ
ID NO:28 or SEQ ID NO:41.
29. The immunogenic fragment of claim 24, wherein the naturally
occurring PcpA is from Streptococcus pneumoniae serotype 6.
30. The immunogenic fragment of claim 24, wherein the fragment
comprises SEQ ID NO:45 with one or more conservative amino acid
substitutions.
31. The immunogenic fragment of claim 24, wherein the fragment
comprises SEQ ID NO:45.
32. A composition comprising the immunogenic fragment of claim 24
and a pharmaceutically acceptable carrier.
33. The composition of claim 32, further comprising an
adjuvant.
34. The composition of claim 32, further comprising an immunogenic
Staphylococcus polypeptide.
35. The composition of claim 32, further comprising an immunogenic
fragment of PspA, pneumolysin, or a combination thereof.
36. The composition of claim 32, further comprising an immunogenic
fragment of pneumolysin.
37. The composition of claim 32, wherein the composition is
suitable for administration to a mucosal surface.
38. The composition of claim 37, wherein the composition is a nasal
spray.
39. The composition of claim 37, wherein the composition is a
nebulizer solution.
40. The composition of claim 37, wherein the composition is an
aerosol inhalant.
41. A container comprising the composition of claim 32.
42. The container of claim 41, wherein the container is a nasal
sprayer.
43. The container of claim 41, wherein the container is a
nebulizer.
44. The container of claim 41, wherein the container is an
inhaler.
45. A method of generating antibodies specific to PcpA in a subject
comprising administering to the subject the immunogenic fragment of
claim 1.
46. A method of preventing or reducing pneumococcal nasal carriage
in a subject comprising administering to the subject the
immunogenic fragment of claim 1.
47. A method of reducing the risk of a pneumococcal infection in a
subject comprising administering to the subject the immunogenic
fragment of claim 1.
48. The method of claim 47, wherein the pneumococcal infection is
meningitis.
49. The method of claim 47, wherein the pneumococcal infection is
otitis media.
50. The method of claim 47, wherein the pneumococcal infection is
pneumonia.
51. The method of claim 47, wherein the pneumococcal infection is
hemolytic uremia.
52. The method of claim 47, wherein the administration of the
immunogenic fragment does not eliminate pneumococcal nasal
carriage.
53. The method of claim 47, further comprising administering a
second immunogenic fragment selected from the group consisting of
an immunogenic fragment of PspA, pneumolysin, or a combination
thereof.
54. The method of claim 47, further comprising administering an
immunogenic fragment of pneumolysin.
55. An isolated polypeptide comprising an amino acid sequence at
least 90% identical to the amino acid sequence of SEQ ID NO:41.
56. An isolated polypeptide comprising an amino acid sequence at
least 90% identical to the amino acid sequence of SEQ ID NO:45.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Ser. No.
60/822,715, filed Aug. 17, 2006; U.S. Ser. No. 60/827,348, filed
Sep. 28, 2006; and U.S. Ser. No. 60/917,178, filed May 10, 2007,
which are incorporated by reference herein in their entireties.
BACKGROUND
[0003] Streptococcus pneumoniae is a rather ubiquitous human
pathogen, which can infect several organs including lungs, the
central nervous system (CNS), the middle ear, and the nasal tract.
Infection results in various symptoms such as bronchitis,
pneumonia, meningitis, sinus infection, and sepsis. S. pneumoniae
is a major cause of bacterial meningitis in humans and is
associated with significant mortality and morbidity despite
antibiotic treatment (Quagliarello et al., (1992) N. Eng. J. Med.
327: 864-872).
[0004] There are two currently available pneumococcal vaccines. One
is a vaccine for adults composed of 23 different capsular
polysaccharides, which together represent the capsular types of
about 90% of strains causing pneumococcal infection. This vaccine,
however, is not immunogenic in children, an age group with high
susceptibility to pneumococcal infection. In adults the vaccine has
been shown to be about 60% efficacious against bacteremic
pneumonia, but it is less efficacious in adults at higher risk of
pneumococcal infection because of age or underlying medical
conditions (Fedson, and Musher. 2004. "Pneumococcal Polysaccharide
Vaccine," pp. 529-588. In Vaccines. S. A. Plotkin and W. A.
Orenstein (eds.), W. B. Saunders and Co., Philadelphia, Pa.;
Shapiro et al., N. Engl. J. Med. 325:1453-1460 (1991)). This
vaccine has not been shown to be effective against non-bacteremic
pneumococcal pneumonia, the most common form of infection.
[0005] The second available vaccine is a 7-valent conjugate vaccine
that is efficacious against bacteremic pneumococcal infections in
children less than 2 years of age. It has also demonstrated
efficacy against pneumonia (Black et al., Pediatr. Infect. Dis.
21:810-5 (2002); Black et al., Arch. Pediatr 11 (7):843-53 (2004)).
The production of this vaccine is complicated because of the need
to produce 7 different conjugates, which leads to the vaccine being
expensive (about $200/child). Moreover, the vaccine does not do a
good job of covering infections in the developing world where
non-vaccine types of Streptococcus pneumoniae are very common (Di
Fabio et al., Pediatr. Infect. Dis. J. 20:959-967 (2001);
Mulholland, Trop. Med. Int. Health 10:497-500 (2005)). This vaccine
does not work as well against otitis media and colonization as it
does against invasive disease. It has also been shown that the use
of the 7-valent conjugate vaccine has led to an increase in
colonization and disease with strains of capsule types not
represented by the 7 polysaccharides included in the vaccine
(Bogaert et al., Lancet Infect. Dis. 4:144-154 (2004); Eskola et
al., N. Engl. J. Med. 344:403-409 (2001); Mbelle et al., J. Infect.
Dis, 180:1171-1176 (1999)). Therefore, a need remains for effective
treatments for Streptococcus pneumoniae.
SUMMARY
[0006] Compositions and methods for eliciting an immune response
against Streptococcus pneumoniae are described. More particularly,
the present disclosure relates to immunogenic PcpA polypeptides,
including fragments of PcpA and variants thereof, and nucleic acids
that encode the polypeptides. The present disclosure further
relates to methods of making and using the immunogenic
polypeptides. These compositions and methods offer improved
efficacy and efficiency and reduced cost as compared to presently
available compositions and methods designed to reduce or prevent
pneumococcal infection.
DESCRIPTION OF DRAWINGS
[0007] FIG. 1 shows PCR confirmation of pcpA. PCR analysis of
genomic DNA of various S. pneumoniae strains. Primer pair (BGP1
(SEQ ID NO:50) and BGP2 (SEQ ID NO:51)) were used to amplify the
nucleic acid encoding the N-terminal portion of PcpA (including the
LRR region). Lane 1, TIGR4; Lane 2, L82013; Lane 3, D1091B; Lane 4,
BG12730; Lane 5, TJ0893; Lane 6, R6; Lane 7, BG10752; Lane 8, V175;
Lane 9, EF3030; Lane 10, negative control (no template DNA).
[0008] FIG. 2 shows Western blot analysis of PcpA presence under
low Mn2+ conditions. Bacteria were cultured in low Mn2+ medium
until mid-log phase and total cellular protein samples prepared.
Samples were separated by SDS-PAGE, transferred to nitrocellulose
and probe with a rPcpA polyclonal antiserum. Lane 1, JEN11 (pcpA-
mutant); Lane 2, JEN7 (pcpA constitutive mutant); Lane 3, D1091B;
Lane 4, EF5668; Lane 5, BG10752; Lane 6, V175; Lane 7, L82013; Lane
8, BG12730; Lane 9, TJ0893.
[0009] FIG. 3 shows that protection conferred by rPcpA immunization
compared to adjuvant alone was statistically significant in a
murine model of pneumonia. CBA/N mice were subcutaneously immunized
with rPcpA adsorbed to aluminum hydroxide or aluminum hydroxide
alone. Mice were challenged intranasally under light anesthesia,
with 5.times.10.sup.6 CFUs of EF3030. Mice were sacrificed 7 days
post-infection and bacterial counts determined from lung
homogenates (FIG. 3A) and nasal washes (FIG. 3B). Horizontal line
denotes median Log 10 CFUs. (**:p=0.0019, Mann-Whitney).
[0010] FIG. 4 shows that protection conferred against other S.
pneumoniae capsular serotypes by rPcpA immunization versus adjuvant
alone was statistically significant in a murine model of pneumonia.
Mice were challenged with strains (FIG. 4A) TJ0893, serotype 14
(**:p=0.0209); (FIG. 4B) L82016, serotype 6B (**:p=0.0193); or
(FIG. 4C) EF9303, serotype 23F (**:p=0.0388, Mann-Whitney).
Horizontal line denotes median Log 10 CFUs.
[0011] FIG. 5 shows the effect of pcpA inactivation on intranasal
colonization of S. pneumoniae. Mice were challenged intranasally
with 10.sup.6 CFUs of EF3030 or its derivative JEN18. Mice were
sacrificed 7 days post-infection and bacterial counts determined
from nasal washes. Horizontal line denotes median Log 10
CFUs/Nose.
[0012] FIG. 6 shows that protection conferred by rPcpA immunization
versus adjuvant alone was statistically significant in a murine
model of fatal sepsis. CBA/N mice were subcutaneously immunized
with rPcpA adsorbed to aluminum hydroxide or aluminum hydroxide
alone. Mice were challenged intravenously with 300 CFUs of TIGR4
and survival time was monitored for 21 days. Horizontal line
denotes median survival time. (**:p=0.0067, Mann-Whitney).
Surviving mice were euthanized and, upon examination, none had
detectable S. pneumoniae in their blood.
[0013] FIG. 7 shows virulence of TIGR4 and its pcpA inactivated
derivative JEN11 in a murine model of sepsis. Mice were challenged
intravenously with 300 CFUs of TIGR4 or JEN11 and survival time was
monitored for 21 days. Horizontal line denotes median survival
time. (**:p=0.0299, Mann-Whitney).
[0014] FIG. 8 shows that protection was conferred by rPcpA mucosal
immunization compared to adjuvant alone in a murine model of
pneumonia. CBA/N mice were intranasally immunized with rPcpA and
cholera toxin B subunit (CTB) or CTB alone. Mice were challenged
intranasally under light anesthesia, with 5.times.10.sup.6 CFUs of
EF3030. Mice were sacrificed 7 days post-infection and bacterial
counts in the homogenized lungs were determined. Horizontal line
denotes median Log 10 CFUs. (*:p=0.0001, Mann-Whitney).
[0015] FIG. 9 shows adherence of pcpA+ and pcpA- TIGR4 strains
(TIGR4 and JEN11, respectively) to human lung epithelial cells.
A549 human lung epithelial cell monolayers were incubated for 150
minutes with 10.sup.6 CFU of pcpA+ and pcpA- TIGR4 strains that had
been grown under high manganese (High Mn.sup.2+) or low manganese
(Low Mn.sup.2+) growth conditions. The epithelial cells were washed
and lysed. Numbers of adherent pneumococci in each lysate were
determined by quantitative plating on blood agar plates. Log 10 CFU
recovered refers to the number of pneumococci associated with the
lung epithelial cells at the end of the experiment. (**:p=0.0022,
Mann-Whitney).
[0016] FIG. 10 shows pcpA+ and pcpA- TIGR4 strains did not adhere
to human nasal epithelial cells. Detroit562 human nasal epithelial
cell monolayers were incubated for 150 minutes with 10.sup.6 CFU of
pcpA+ and pcpA- TIGR4 strains that had been grown under high
manganese (High Mn.sup.2+) or low manganese (Low Mn.sup.2+) growth
conditions. The cells were then washed and lysed. Numbers of
pneumococci in the lysate were determined by quantitative plating
on blood agar plates. Log 10 CFU recovered refers to the number of
pneumococci at the end of the experiment.
[0017] FIG. 11 shows inhibition of adherence of pneumococci to A549
cells by an antibody to PcpA. A549 human lung epithelial cell
monolayers were incubated with 10.sup.6 CFU of pcpA+ and pcpA-
TIGR4 strains grown in high manganese (High Mn.sup.2+) or low
manganese (Low Mn.sup.2+) without antibody, with 1/100 dilution, or
with 1/50 dilution of PcpA antibody. The cells were washed and
lysed. Numbers of pneumococci in the lysate were determined by
quantitative plating on blood agar plates.
[0018] FIG. 12 shows protection against sepsis using rabbit sera to
PcpA. Rabbit serum was prepared by immunizing a rabbit with 100
.mu.g rPcpA in complete Freund's adjuvant followed two and four
weeks later by 100 .mu.g rPcpA in complete Freund's adjuvant. Sera
was collected two weeks after the final boost and was shown to
contain antibody to PcpA by dot blot assay. Pre-immune sera was
also collected before the start of the immunizations. Mice were
tested in groups of two for the ability of dilutions of the rabbit
anti-sera to protect against fatal pneumococcal infection. Three
groups of mice received 0.1 mL of 1/10, 1/100 or 1/1000 dilutions
of the immune sera intraperitoneally one hour prior to i.v.
challenge with TIGR4. Two mice received 1/10 pre-immune
(non-immune) rabbit serum and two mice received the diluent, PBS,
only. Mice were observed for 500 hours or until time of death. The
two mice receiving 1/10 immune sera lived throughout the
experiment. All other mice died between 40 and 60 hours post
challenge.
[0019] FIG. 13 shows protection against lung infection with PcpA
and pneumolysin (Ply). Mice were immunized three times with 5 .mu.g
of rPcpA, 5 .mu.g of pneumolysin (Ply), or 5 .mu.g of rPcpA plus 5
.mu.g Ply. The first two injections were with alum and the third
injection was with protein alone. The Ply used was wild-type Ply.
Mice were anethesized with isoflurane (MinRAD, Buffalo, N.Y.) and
challenged i.n. with 5.times.10.sup.6 CFU of capsular type 19F
strain EF3030 in 40 .mu.L volume. This procedure results in lung
infection and nasal colonization. Seven days later mice were
sacrificed and homogenized lungs were plated. The CFU observed
indicated that immunization with either PcpA or Ply resulted in
similar levels of protection. Mice immunized with PcpA and Ply
resulted in over 100-fold more protection than control mice and 10
times more protection than Ply or PcpA alone.
[0020] FIG. 14 is a schematic showing the construction of the
plasmid pJMS87 formed by ligation of the plasmid pET30a and a
nucleic acid encoding a fragment of PcpA (.DELTA.SP.DELTA.CBD PcpA
from Streptococcus pneumoniae strain B6).
[0021] FIGS. 15A and 15B are graphical representations of the
protection conferred by immunizing mice with the recombinant PcpA
(rPcpA) of Example 8 (10 to 0.625 .mu.g/dose) in a murine sepsis
model. Mice were challenged intraperitoneally with 300 CFU of
strain WUBM3. FIG. 15A shows that rPcpA immunized mice at each dose
were significantly protected when compared to the adjuvant control
group (PBS) (Fisher Exact Test) over a period of time. FIG. 15B
shows the level of protection in each group at day 7 post
challenge.
[0022] FIG. 16 is a graphical representation of the protection
conferred by immunization with the rPcpA of Example 8 in a mouse
pneumonia model. Groups 1 to 6 were immunized with placebo (Group
1), PspA (Group 2) or rPcpA (Groups 3 to 6). Approximately 14 CBA/N
mice per group were immunized at day 0 subcutaneously (s.c.) with a
primary dose of immunogen. A second immunization was performed at
day 21 and a third immunization at day 43. On day 63 the mice were
challenged intranasally with 5.6.times.10.sup.6 CFU of S.
pneumoniae strain EF3030. Five days post infection CFU were
determined in homogenized lung tissue.
DETAILED DESCRIPTION
[0023] Immunogenic fragments and variants of PcpA are described
herein along with methods of making and using the fragments and
variants. PcpA, which was initially identified as a choline binding
protein (CBP) of Streptococcus pneumoniae, differs from the CBP
proteins PspA and PspC (Sanchez-Beato et al., FEMS Microbiol. Lett.
164:207-214 (1998)), and mutations in pcpA have been shown to cause
(1) reduced virulence in the lung, in bacteremia, and in the
nasopharynx of mice in competition models in which a mutant strain
and a wild type strain are allowed to compete (Hava and Camilli,
Mol. Microbiol. 45:1389-1406 (2002)); (2) reduced virulence and
bacterial load in a non-competition comparison of lung colonization
(Johnston et al., Infect. Immun. 74:1171-1180 (2006)); (3) reduced
ability of the invasive strain TIGR4 (capsular type 4) S.
pneumoniae to cause sepsis in CBA/CaHN-Btkxid/J mice; and (4)
reduced lung colonization in competition with wild type strains.
The present disclosure provides the first evidence that PcpA is
immunogenic and, in particular, that fragments and variants of PcpA
are immunogenic.
[0024] Immunogenic polypeptides comprise the full-length PcpA amino
acid sequence (in the presence or absence of the signal sequence),
fragments thereof, and variants thereof. Full-length PcpA includes
GenBank Accession No. CAB04758 from Streptococcus pneumoniae strain
B6, GenBank Accession No. NP.sub.--346554 from S. pneumoniae strain
TIGR4 and GenBank Accession No. NP.sub.--359536 from S. pneumoniae
strain R6.
[0025] Optionally, immunogenic polypeptides of PcpA comprise one or
more leucine rich regions (LRRs). These LLRs are present in
naturally occurring PcpA or have about 60 to about 99% sequence
identity, including, for example, 80%, 85%, 90% or 95% sequence
identity to the naturally occurring LRRs. LRRs in the mature PcpA
protein (i.e., the protein lacking the signal peptide) can be found
within SEQ ID NOs: 1, 2, 41 or 45.
[0026] An immunogenic polypeptide of PcpA optionally lacks the
choline binding anchor sequence typically present in the naturally
occurring mature PcpA protein. The naturally occurring sequence of
the choline binding anchor is SEQ ID NO:52 of the mature PcpA
protein. More particularly, an immunogenic polypeptide comprises an
N-terminal region of naturally occurring PcpA with one or more
amino acid substitutions and about 60 to about 99% sequence
identity or any identity in between, e.g., 80, 85, 90 and 95%
identity, to the naturally occurring PcpA. The N-terminal region
may comprise the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 41
or 45, in the presence or absence of one or more conservative amino
acid substitutions and in the presence or absence of the signal
sequence. The N-terminal region may comprise an amino acid sequence
having about 60 to about 99% sequence identity (or any identity in
between 80 to 99% identity) to SEQ ID NOs: 1, 2, 3, 4, 41 or
45.
[0027] Immunogenic fragments of SEQ ID NOs:1, 2, 3, 4, 41 or 45
comprise 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130,
140, 150, 160, 170, 180, 190 and 191 amino acid residues of SEQ ID
NOs: 1, 2, 3, 4, 41 or 45 or any number of amino acid residues
between 5 and 191. Examples of such fragments include, by way of
example, amino acids comprising LEKIEDRAFD (SEQ ID NO:5),
FSELEEIELP (SEQ ID NO:6), ASLEYIGTSA (SEQ ID NO:7), FSFSQKLKKL (SEQ
ID NO:8), TFSSSSKLEL (SEQ ID NO:9), ISHEAFANLS (SEQ ID NO:10),
NLEKLTLPKS (SEQ ID NO:11), VKTLGSNLFR (SEQ ID NO:12), LTTSLNMLML
(SEQ ID NO:13), LTTSLKHVDV (SEQ ID NO:14), RGMIVASVDG (SEQ ID
NO:15), EEGNESFASVDG (SEQ ID NO:16), VSFQSKTQLI (SEQ ID NO:17),
VLFSKDKTQLI (SEQ ID NO:18), YYPSQKNDES (SEQ ID NO:19), YKTPKETKEL
(SEQ ID NO:20), ASYSFNKNSY (SEQ ID NO:21), LKKLELNEGL (SEQ ID
NO:22), QKIGTFAFAD (SEQ ID NO:23), EKIGTFAFAD (SEQ ID NO:24),
ATKLEEISLP (SEQ ID NO:25), AIKLEEISLP (SEQ ID NO:26), NSLETIERLA
(SEQ ID NO:27), FYGNLELKELIL (SEQ ID NO:28).
[0028] Optionally, immunogenic polypeptides of PcpA lack the LRRs.
Examples of immunogenic polypeptides lacking the LRR include SEQ ID
NO:29, SEQ ID NO:30, and SEQ ID NO:31 or any immunogenic fragment
of either SEQ ID NOs:29, 30 or 31 comprising 5 or more amino acid
residues. SEQ ID NOs:30 and 31 comprise the residues C-terminal to
the leucine-rich region of PcpA.
[0029] Variants of the immunogenic polypeptides described herein
may comprise one or more conservative amino acid substitutions.
Variants of the immunogenic polypeptides include amino acid
sequence having about 60 to about 99% sequence identity (or any
identity in between 60 and 99% identity) to SEQ ID NOs:1 to 31, 41
and 45 or any fragment thereof. Variants are selected for their
immunogenic capacity using methods taught herein.
[0030] The immunogenic polypeptides of PcpA described herein
include fragments of PcpA and variants of such fragments. Variants
of PcpA fragments may comprise amino acid sequence modifications.
For example, amino acid sequence modifications include
substitutional, insertional or deletional changes. Substitutions,
deletions, insertions or any combination thereof may be combined in
a single variant so long as the variant is an immunogenic
polypeptide. Insertions include amino and/or carboxyl terminal
fusions as well as intrasequence insertions of single or multiple
amino acid residues. Insertions ordinarily will be smaller
insertions than those of amino or carboxyl terminal fusions, for
example, on the order of one to four residues. Deletions are
characterized by the removal of one or more amino acid residues
from the protein sequence. Typically, no more than about from 2 to
6 residues are deleted at any one site within the protein molecule.
These variants ordinarily are prepared by site specific mutagenesis
of nucleotides in the DNA encoding the protein, thereby producing
DNA encoding the variant, and thereafter expressing the DNA in
recombinant cell culture. Techniques for making substitution
mutations at predetermined sites in DNA having a known sequence are
well known and include, but are not limited to, M13 primer
mutagenesis and PCR mutagenesis. Amino acid substitutions are
typically of single residues but can occur at a number of different
locations at once. Substitutional variants are those in which at
least one residue has been removed and a different residue inserted
in its place. Such substitutions generally are made in accordance
with the following Table 1 and are referred to as conservative
substitutions. However, others are well known to those of skill in
the art.
TABLE-US-00001 TABLE 1 Conservative Amino Acid Substitutions
Exemplary Original Residue Substitutions Arg Lys Asn Gln Asp Glu
Cys Ser Gln Asn Glu Asp Gly Pro His Gln Ile Leu, Val Leu Ile, Val
Lys Arg, Gln Met Leu, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr
Tyr Trp, Phe Val Ile, Leu
[0031] Variants as used herein may also include naturally occurring
pcpA alleles from alternate strains that exhibit polymorphisms at
one or more sites within the homologous pcpA gene. Variants can be
produced by conventional molecular biology techniques. The variants
are described herein relative to sequence identity as compared to
the naturally occurring pcpA. Those of skill in the art readily
understand how to determine the sequence identity of two
polypeptides or nucleic acids. For example, the sequence identity
can be calculated after aligning the two sequences so that the
identity is at its highest level. Alignments are dependent to some
extent upon the use of the specific algorithm in alignment
programs. This could include, for example, the local homology
algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), the
homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol.
48: 443 (1970), by the search for similarity method of Pearson and
Lipman, PNAS USA 85: 2444 (1988), by computerized implementations
of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the
Wisconsin Genetics Software Package, Genetics Computer Group, 575
Science Dr., Madison, Wis.), BLAST and BLAST 2.0 and algorithms
described by Altschul et al., Nucleic Acids Res. 25:3389-3402,
1977; Altschul, et al., J. Mol. Biol. 215:403-410, 1990; Zuker, M.
Science 244:48-52, 1989; Jaeger et al. PNAS USA 86:7706-7710, 1989
and Jaeger et al. Methods Enzymol. 183:281-306, 1989. Each of these
references is incorporated by reference at least for the material
related to alignment and calculation of identity. It is understood
that any of the methods typically can be used and that in certain
instances the results of these various methods may differ. Where
sequence identity is provided as, for example, 95%, then such
identity must be detectable with at least one of the accepted
methods of calculation.
[0032] The immunogenic polypeptides described herein can include
one or more amino acid analogs or non-naturally occurring
stereoisomers. These amino acid analogs and stereoisomers can
readily be incorporated into polypeptide chains by charging tRNA
molecules with the amino acid of choice and engineering genetic
constructs that utilize, for example, amber codons, to insert the
analog amino acid into a peptide chain in a site specific way
(Thorson et al., Methods in Molec. Biol. 77:43-73 (1991), Zoller,
Current Opinion in Biotechnology, 3:348-354 (1992); Ibba,
Biotechnology & Genetic Engineering Reviews 13:1.97-216 (1995),
Cahill et al., TIBS, 14(10):400-403 (1989); Benner, TIB Tech,
12:158-163 (1994); Ibba and Hennecke, Bio/technology, 12:678-682
(1994) all of which are herein incorporated by reference at least
for material related to amino acid analogs). Immunogenic fragments
can be produced that resemble peptides but which are not connected
via a natural peptide linkage. For example, linkages for amino
acids or amino acid analogs can include CH2NH--, --CH2S--,
--CH2-CH2-, --CH.dbd.CH-- (cis and trans), --COCH2-, --CH(OH)CH2-,
and --CHH2SO-- (These and others can be found in Spatola, A. F.
"Peptide backbone modifications: A structure-activity analysis of
peptides containing amide bond surrogates, conformational
constraints, and related backbone modifications." In Chemistry and
Biochemistry of Amino Acids, Peptides, and Proteins, pp. 267-357.
Weinstein, B. editor, Marcel Dekker, New York, N.Y. (1983); Morley,
Trends in Pharm. Sci. 1(2):463-468 (1980); Hudson, et al., Int J
Pept Prot Res 14:177-185 (1979) (--CH2NH--, CH2CH2-); Spatola et
al. Life Sci 38:1243-1249 (1986) (--CH H2-S); Hann, Journal of the
Chemical Society. Perkin Transactioins I pp. 307-314 (1982)
(--CH--CH--, cis and trans); Almquist et al., J. Med. Chem.
23:1392-1398 (1980) (--COCH2-); Jennings-White et al., Tetrahedron
Lett 23:2533 (1982) (--COCH2-); European Publication No. EP0045665
to Szelke, et al. (1982) (--CH(OH)CH2-); Holladay et al.,
Tetrahedron. Lett 24:4401-4404 (1983) (--C(OH)CH2-); and Hruby Life
Sci 31:189-199 (1982) (--CH2-S--); each of which is incorporated
herein by reference at least for the material regarding
linkages).
[0033] Amino acid analogs and stereoisomers often have enhanced or
desirable properties, such as, more economical production, greater
chemical stability, enhanced pharmacological properties (half-life,
absorption, potency, efficacy, etc.), altered specificity (e.g., a
broad-spectrum of biological activities), and others. For example,
D-amino acids can be used to generate more stable peptides, because
D amino acids are not recognized by naturally occurring peptidases.
Systematic substitution of one or more amino acids of a consensus
sequence with a D-amino acid of the same type (e.g., D-lysine in
place of L-lysine) can be used to generate more stable peptides.
Cysteine residues can be used to cyclize or attach two or more
peptides together. This can be beneficial to constrain peptides
into particular conformations. (Rizo and Gierasch Ann. Rev.
Biochem. 61:387 (1992), incorporated herein by reference).
[0034] A composition comprising an immunogenic polypeptide of PcpA
and a pharmaceutically acceptable carrier are described herein.
Optionally, the composition further comprises an adjuvant.
Compositions comprising the immunogenic polypeptide may contain
combinations of other immunogenic polypeptides, including, for
example, an immunogenic Staphylococcus polypeptide or immunogenic
fragments of PspA, pneumolysin, or a combination thereof.
[0035] Optionally, the compositions described herein are suitable
for administration to a mucosal surface. The composition can be a
nasal spray, a nebulizer solution, or an aerosol inhalant, for
example. Thus the composition may be present in a container and the
container may be a nasal sprayer, a nebulizer, or an inhaler.
[0036] By pharmaceutically acceptable carrier is meant a material
that is not biologically or otherwise undesirable, i.e., the
material may be administered to a subject, along with the
immunogenic fragment of PcpA, without causing any undesirable
biological effects or interacting in a deleterious manner with any
of the other components of the pharmaceutical composition in which
it is contained. The carrier would naturally be selected to
minimize any degradation of the active ingredient and to minimize
any adverse side effects in the subject, as would be well known to
one of skill in the art.
[0037] Suitable carriers and their formulations are described in
Remington: The Science and Practice of Pharmacy, 21.sup.st Edition,
David B. Troy, ed., Lippicott Williams & Wilkins (2005).
Typically, an appropriate amount of a pharmaceutically-acceptable
salt is used in the formulation to render the formulation isotonic.
Examples of the pharmaceutically-acceptable carriers include, but
are not limited to, sterile water, saline, buffered solutions like
Ringer's solution, and dextrose solution. The pH of the solution is
generally from about 5 to about 8 or from about 7 to about 7.5.
Other carriers include sustained release preparations such as
semipermeable matrices of solid hydrophobic polymers containing the
immunogenic PcpA polypeptides. Matrices are in the form of shaped
articles, e.g., films, liposomes or microparticles. It will be
apparent to those persons skilled in the art that certain carriers
may be more preferable depending upon, for instance, the route of
administration and concentration of composition being administered.
Carriers are those suitable for administration of the PcpA
immunogenic fragments to humans or other subjects.
[0038] Pharmaceutical compositions may include carriers,
thickeners, diluents, buffers, preservatives, surface active
agents, adjuvants, immunostimulants, in addition to the immunogenic
polypeptide. Pharmaceutical compositions may also include one or
more active ingredients such as antimicrobial agents,
anti-inflammatory agents and anesthetics.
[0039] Adjuvants include metallic salts, such as aluminium salts,
and are well known in the art as providing a safe excipient with
adjuvant activity. The mechanism of action of these adjuvants are
thought to include the formation of an antigen depot such that
antigen may stay at the site of injection for up to 3 weeks after
administration, and also the formation of antigen/metallic salt
complexes which are more easily taken up by antigen presenting
cells. In addition to aluminium, other metallic salts have been
used to adsorb antigens, including salts of zinc, calcium, cerium,
chromium, iron, and berilium. The hydroxide and phosphate salts of
aluminium are the most common. Formulations or compositions
containing aluminium salts, antigen, and an additional
immunostimulant are known in the art. An example of an
immunostimulant is 3-de-O-acylated monophosphoryl lipid A
(3D-MPL).
[0040] The adjuvant and/or immunostimulant can be administered
concomitantly with the polypeptide composition, immediately prior
to, or after administration of the composition. Optionally, the
composition further comprises the adjuvant. Adjuvant formulations
include, for example, an agent that targets mucosal inductive
sites. The adjuvant may optionally be selected from the group
including, but not limited to, cytokines, chemokines, growth
factors, angiogenic factors, apoptosis inhibitors, and combinations
thereof. When a cytokine is chosen as an adjuvant, the cytokine may
be selected from the group including, but not limited to,
interleukins including IL-1, IL-3, IL-2, IL-5, IL-6, IL-12, IL-15
and IL-18; transforming growth factor-beta (TGF-.beta.);
granulocyte macrophage colony stimulating factor (GM-CSF);
interferon-gamma (IFN-.gamma.); or any other cytokine that has
adjuvant activity. Portions of cytokines, or mutants or mimics of
cytokines (or combinations thereof), having adjuvant activity or
other biological activity can also be used in the compositions and
methods of the present invention.
[0041] When a chemokine is chosen as an adjuvant, the chemokine may
optionally be selected from a group including, but not limited to,
Lymphotactin, RANTES, LARC, PARC, MDC, TAR C, SLC and FKN. When an
apoptosis inhibitor is chosen as an adjuvant, the apoptosis
inhibitor may optionally be selected from the group including, but
not limited to, inhibitors of caspase-8, and combinations thereof.
When an angiogenic factor is chosen as an adjuvant, the angiogenic
factor may optionally be selected from the group including, but not
limited to, a basic fibroblast growth factor (FGF), a vascular
endothelial growth factor (VEGF), a hyaluronan (HA) fragment, and
combinations thereof.
[0042] Other examples of substantially non-toxic, biologically
active adjuvants include hormones, enzymes, growth factors, or
biologically active portions thereof. Such hormones, enzymes,
growth factors, or biologically active portions thereof can be of
human, bovine, porcine, ovine, canine, feline, equine, or avian
origin, for example, and can be tumor necrosis factor (TNF),
prolactin, epidermal growth factor (EGF), granulocyte colony
stimulating factor (GCSF), insulin-like growth factor (IGF-1),
somatotropin (growth hormone) or insulin, or any other hormone or
growth factor whose receptor is expressed on cells of the immune
system.
[0043] Adjuvants also include bacterial toxins, e.g., the cholera
toxin (CT), the E. coli heat-labile toxin (LT), the Clostridium
difficile toxin A and the pertussis toxin (PT), or combinations,
subunits, toxoids, chimera, or mutants thereof. For example, a
purified preparation of native cholera toxin subunit B (CTB) can be
used. Fragments, homologs, derivatives, and fusions to any of these
toxins are also suitable, provided that they retain adjuvant
activity. Suitable mutants or variants of adjuvants are described,
e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly
LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant).
Additional LT mutants that can be used in the methods and
compositions include, e.g., Ser-63-Lys, Ala-69-Gly, Glu-110-Asp,
and Glu-112-Asp mutants. Other adjuvants, such as RH3-ligand;
CpG-motif oligonucleotide; a bacterial monophosphoryl lipid A(MPLA)
of, e.g., E. coli, Salmonella minnesota, Salmonella typhimurium, or
Shigella exseri; saponins (e.g., QS21), or polylactide glycolide
(PLGA) microspheres, can also be used. Possible other adjuvants are
defensins and CpG motifs.
[0044] Provided are methods of making and using the immunogenic
polypeptides described herein and compositions useful in such
methods. The polypeptides can be generated using standard molecular
biology techniques and expression systems. (See, for example,
Molecular Cloning: A Laboratory Manual, Third Edition by Sambrook
et al., Cold Spring Harbor Press, 2001). For example, a fragment of
the pcpA gene that encodes an immunogenic polypeptide may be
isolated and the polynucleotide encoding the immunogenic
polypeptide may be cloned into any commercially available
expression vector (such as pBR322 and pUC vectors (New England
Biolabs, Inc., Ipswich, Mass.)) or expression/purification vectors
(such as GST fusion vectors (Pfizer, Inc., Piscataway, N.J.)) and
then expressed in a suitable prokaryotic, viral or eukaryotic host.
Purification may then be achieved by conventional means or, in the
case of a commercial expression/purification system, in accordance
with a manufacturer's instructions.
[0045] Provided herein are nucleic acids comprising a sequence that
encodes any one of SEQ ID NOs:1 to 31, 41 and 45. Provided herein
is a nucleic acid comprising SEQ ID NOs:32, 33 and 47, which encode
full length PcpA proteins or fragments thereof. Also provided are
degenerate variants and fragments of these degenerate variants of
SEQ ID NOs:32, 33 and 47.
[0046] Nucleic acids that encode SEQ ID NOs:1 and 2 or fragments
thereof are described, including SEQ ID NO:34 and SEQ ID NO:35,
respectively, or degenerate variants or fragments thereof.
[0047] Nucleic acids that encode SEQ ID NOs:3 and 4 or fragments
thereof include, but are not limited to, SEQ ID NOs:36 and 37,
respectively, or degenerate variants or fragments thereof.
[0048] Nucleic acids that encode SEQ ID NO:41 or fragments thereof
are described, including SEQ ID NO:42 or degenerate variants or
fragments thereof.
[0049] Nucleic acids that encode SEQ ID NO:45 or fragments thereof
are described, including SEQ ID NO:46 or degenerate variants or
fragments thereof.
[0050] Exemplary nucleic acids that encode SEQ ID NO:29 or
fragments thereof include SEQ ID NO:38 or degenerate variants or
fragments thereof.
[0051] More specifically, provided herein is a nucleic acid
comprising any one of the sequences designated as SEQ ID NOs:32 to
38, 42, 46 and 47 or degenerate variants thereof.
[0052] Also provided are isolated nucleic acids comprising a
sequence that hybridizes under highly stringent conditions to all
or any portion of a hybridization probe having a nucleotide
sequence that comprises SEQ ID NOs:32 to 38, 42, 46 and 47 or the
complement of SEQ ID NOs:32 to 38, 42, 46 and 47 or any fragment of
the sequence or complement thereof. The hybridizing portion of the
hybridizing nucleic acid is typically at least 15 (e.g., 15, 20,
25, 30, 40, or more) nucleotides in length. The hybridizing portion
is at least 80% (e.g., 85%, 90% or 95%) identical to the a portion
of the sequence to which it hybridizes. Hybridizing nucleic acids
are useful, for example, as cloning probes, primers (e.g., PCR
primer), or a diagnostic probe. Nucleic acid duplex or hybrid
stability is expressed as the melting temperature or Tm, which is
the temperature at which a probe dissociates from a target DNA.
This melting temperature is used to define the required stringency
conditions. If sequences are identified that are related and
substantially identical to the probe, rather than identical, then
it is useful to first establish the lowest temperature at which
only homologous hybridization occurs with a particular
concentration of salt (e.g., SSC or SSPE). Assuming that a 1%
mismatching results in a 1.degree. C. decrease in Tm, the
temperature of the final wash in the hybridization reaction is
reduced accordingly (for example, if sequences having more than 95%
identity are sought, the final wash temperature is decreased by
5.degree. C.). In practice, the change in Tm can be between 0.5 and
1.5.degree. C. per 1% mismatch. Highly stringent conditions involve
hybridizing at 68.degree. C. in 5.times.SSC/5.times.Denhardt's
solution/1.0% SDS, and washing in 0.2.times.SSC/0.1% SDS at room
temperature. Moderately stringent conditions include washing in
3.times.SSC at 42.degree. C. Salt concentrations and temperatures
can be varied to achieve the optimal level of identity between the
probe and the target nucleic acid. Additional guidance regarding
such conditions is readily available in the art, for example, in
Molecular Cloning: A laboratory Manual, Third Edition by Sambrook
et al., Cold Spring Harbor Press, 2001.
[0053] Thus, it is understood that the nucleic acids that can
encode the aforementioned peptide sequences, variants and fragments
thereof are disclosed. This would include all degenerate sequences
related to a specific protein sequence, i.e., all nucleic acids
having a sequence that encodes one particular protein sequence as
well as all nucleic acids, including degenerate nucleic acids,
encoding the disclosed variants and derivatives of the protein
sequences. Thus, while each particular nucleic acid sequence may
not be written out herein, it is understood that each and every
sequence is in fact disclosed and described herein through the
disclosed protein sequence.
[0054] Also disclosed are vectors comprising the nucleic acids
described herein. Thus, provided is a vector that comprises a
nucleic acid that encodes an immunogenic polypeptide (e.g., SEQ ID
NOs:1 to 31, 41 or 45 or fragments or variants thereof). The vector
can comprise any of the nucleic acid sequences SEQ ID NOs:32 to 38,
42 and 47 or degenerate variants or fragments thereof. Optionally,
the nucleic acid of the vector is operably linked to an expression
control sequence (e.g., a promoter or enhancer or both). Suitable
expression vectors are well known to those of skill in the art and
commercially available from a variety of sources such as Novagen,
Inc., Madison, Wis.; Invitrogen Corporation, Carlsbad, Calif.; and
Promega Corporation, Madison, Wis.
[0055] A cultured cell comprising the vector is also provided. The
cultured cell can be a cultured cell transfected with the vector or
a progeny of the cell, wherein the cell expresses the immunogenic
polypeptide. Suitable cell lines are known to those of skill in the
art and are commercially available, for example, through the
American Type Culture Collection (ATCC).
[0056] The transfected cells can be used in a method of producing
an immunogenic polypeptide. The method comprises culturing a cell
comprising the vector under conditions that allow expression of the
immunogenic polypeptide, optionally under the control of an
expression sequence. The immunogenic polypeptide can be isolated
from the cell or the culture medium using standard protein
purification methods.
[0057] The immunogenic polypeptides can be made using standard
enzymatic cleavage of larger polypeptides or proteins or can be
generated by linking two or more peptides or polypeptides together
by protein chemistry techniques. For example, peptides or
polypeptides can be chemically synthesized using currently
available laboratory equipment using either Fmoc
(9-fluorenylmethyloxycarbonyl) or Boc (tert-butyloxycarbonyl)
chemistry. (Applied Biosystems, Inc., Foster City, Calif.). By
peptide condensation reactions, native chemical ligation, solid
phase chemistry, or enzymatic ligation, two fragments can be
covalently joined via a peptide bond at their carboxyl and amino
termini to form an immunogenic PcpA polypeptide. (Synthetic
Peptides: A User Guide., Grant, ed., W.H. Freeman and Co., New
York, N.Y. (1992); Principles of Peptide Synthesis., Bodansky and
Trost, eds. Springer-Verlag Inc., New York, N.Y. (1993); Abrahmsen
L, et al., Biochemistry, 30:4151 (1991); Dawson et al. Science,
266:776-779 (1994); Solid Phase Peptide Synthesis, 2.sup.nd
Edition, Stewart, ed., Pierce Chemical Company, Rockford, Ill.,
(1984), all of which are incorporated herein by reference for the
methods described therein).
[0058] The immunogenic polypeptides and compositions comprising one
or more polypeptides may be used to generate antibodies. Thus, a
method of generating antibodies specific to PcpA in a subject
comprises administering to the subject a immunogenic PcpA fragment
described herein. Also provided herein are antibodies that bind the
PcpA polypeptides as well as antibody fragments that bind the PcpA
polypeptides.
[0059] Antibodies may be polyclonal or monoclonal, may be fully
human or humanized, and include naturally occurring antibodies and
single-chain antibodies. Antibodies can be made in vivo by
administering to a subject an immunogenic PcpA polypeptide.
Antibody production includes making monoclonal antibodies using
hybridoma methods. Hybridoma methods are well known in the art and
are described by Kohler and Milstein, Nature, 256:495 (1975) and
Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring
Harbor Publications, New York, (1988), which are incorporated by
reference in their entirety for the methods described therein.
[0060] Methods for the production of single-chain antibodies are
well known to those of skill in the art. See, for example, U.S.
Pat. No. 5,359,046, (incorporated herein by reference in its
entirety for such methods). A single chain antibody is created by
fusing together the variable domains of the heavy and light chains
using a short peptide linker, thereby reconstituting an antigen
binding site on a single molecule. Single-chain antibody variable
fragments (scFvs) in which the C-terminus of one variable domain is
tethered to the N-terminus of the other variable domain via a 15 to
25 amino acid peptide or linker have been developed without
significantly disrupting antigen binding or specificity of the
binding. The linker is chosen to permit the heavy chain and light
chain to bind together in their proper conformational orientation.
See, for example, Huston, J. S., et al., Methods in Enzym.
203:46-121 (1991), which is incorporated herein by reference for
its material regarding linkers.
[0061] Fully human and humanized antibodies to the PcpA
polypeptides may be used in the methods described herein. Humanized
antibodies include human immunoglobulins (recipient antibody) in
which residues from a complementary determining region (CDR) of the
recipient are replaced by residues from a CDR of a non-human
species (donor antibody) such as mouse, rat or rabbit having the
desired specificity, affinity and capacity. In some instances, Fv
framework residues of the human immunoglobulin are replaced by
corresponding non-human residues. Transgenic animals (e.g., mice)
that are capable, upon immunization, of producing a full repertoire
of human antibodies (i.e., fully human antibodies) may be employed.
The homozygous deletion of the antibody heavy chain joining region
(J(H)) gene in chimeric and germ-line mutant mice results in
complete inhibition of endogenous antibody production. Transfer of
the human germ-line immunoglobulin gene array in such germ-line
mutant mice results in the production of human antibodies upon
antigen challenge (see, e.g., Jakobovits et al., PNAS USA,
90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993);
Bruggemann et al., Year in Immuno., 7:33 (1993)). Human antibodies
can also be produced in phage display libraries (Hoogenboom et al.,
J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581
(1991)). The techniques of Cote et al. and Boerner et al. also
describe methods for the preparation of human monoclonal antibodies
(Cole, et al., "The EBV-hybridoma technique and its application to
human lung cancer." In, Monoclonal Antibodies and Cancer Therapy,
Volume 27, Reisfeld and Sell, eds., pp. 77-96, Alan R. Liss, Inc.,
New York, N.Y., (1985); Boerner et al., J. Immunol., 147(1):86-95
(1991)). These references are incorporated by reference in their
entirety for the methods described therein.
[0062] Antibody fragment as used herein includes F(ab')2, Fab', and
Fab fragments, including hybrid fragments. Such fragments of the
antibodies retain the ability to bind a specific PcpA polypeptide.
Methods can be used to construct (ab) expression libraries (see
e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and
effective identification of monoclonal F(ab) fragments with the
desired specificity for a PcpA polypeptide. Antibody fragments that
contain the idiotypes to the polypeptide may be produced by
techniques known in the art including, but not limited to: (i) an
F(ab')2 fragment produced by pepsin digestion of an antibody
molecule; (ii) an Fab fragment generated by reducing the disulfide
bridges of an F(ab')2 fragment; (iii) an F(ab) fragment generated
by the treatment of the antibody molecule with papain and a
reducing agent and (iv) F(v) fragments.
[0063] Described herein is a method of reducing the risk of a
pneumococcal infection in a subject comprising administering to the
subject the immunogenic fragment of PcpA or a composition thereof.
Pneumococcal infections include, for example, meningitis, otitis
media, pneumonia, sepsis, or hemolytic uremia. Thus, the risk of
any one or more of these infections are reduced by the methods
described herein. The method can further comprise the step of
administering a second immunogenic fragment. The second immunogenic
fragment can be from PspA, pneumolysin, or a combination thereof.
The second immunogenic fragment can be administered at the same
time, before or after the immunogenic fragment of PcpA.
[0064] The compositions comprising a PcpA polypeptide or fragments
thereof may be administered orally, parenterally (e.g.,
intravenously), intramuscularly, intraperitoneally, transdermally
or topically, including intranasal administration or administration
to any part of the respiratory system. As used herein,
administration to the respiratory system means delivery of the
compositions into the nose and nasal passages through one or both
of the nares or through the mouth, including delivery by a spraying
mechanism or droplet mechanism, through aerosolization or
intubation.
[0065] The exact amount of the compositions and PcpA polypeptides
or fragments required will vary from subject to subject, depending
on the species, age, weight and general condition of the subject,
the polypeptide used, and its mode of administration. Thus, it is
not possible to specify an exact amount for every composition.
However, an appropriate amount can be determined by one of ordinary
skill in the art given the description herein. Furthermore,
multiple doses of the PcpA polypeptide or fragment may be used
including, for example, in a prime and boost regimen.
[0066] Combinations of PspA and pneumolysin are more efficacious
that either protein alone at eliciting protective immunity against
pneumonia and sepsis (Briles et al., J. Infect. Immun. 188:339-48
(2003); Ogunniyi et al., Infect. Immun. 68:3028-33 (2000)). Thus,
the compositions comprising PcpA or immunogenic fragments can
optionally comprise a second immunogenic fragment of PcpA, PspA, or
pneumolysin, or a combination thereof. These references are
incorporated herein by reference in their entireties for methods of
combining and methods of administration for the proteins taught
therein.
[0067] Any of the aforementioned treatments can be used in any
combination with the compositions described herein. Combinations
may be administered either concomitantly (e.g., as an admixture),
separately but simultaneously (e.g., via separate intravenous lines
into the same subject), or sequentially (e.g., one of the compounds
or agents is given first followed by the second). Thus, the term
combination is used to refer to either concomitant, simultaneous,
or sequential administration of two or more agents.
[0068] It must be noted that, as used in the specification and the
appended claims, the singular forms a, an and the include plural
referents unless the context clearly dictates otherwise. Thus, for
example, reference to an antigenic fragment includes mixtures of
antigenic fragments, reference to a pharmaceutical carrier or
adjuvant includes mixtures of two or more such carriers or
adjuvants.
[0069] As used herein, a subject is meant an individual. Thus, the
subject can include domesticated animals, such as cats and dogs,
livestock (e.g., cattle, horses, pigs, sheep, and goats),
laboratory animals (e.g., mice, rabbits, rats, guinea pigs) and
birds. In one aspect, the subject is a mammal such as a primate or
a human.
[0070] Optional or optionally means that the subsequently described
event or circumstance can or cannot occur, and that the description
includes instances where the event or circumstance occurs and
instances where it does not. For example, the phrase optionally the
composition can comprise a combination means that the composition
may comprise a combination of different molecules or may not
include a combination such that the description includes both the
combination and the absence of the combination (i.e., individual
members of the combination).
[0071] Ranges may be expressed herein as from about one particular
value, and/or to about another particular value. When such a range
is expressed, another aspect includes from the one particular value
and/or to the other particular value. Similarly, when values are
expressed as approximations, by use of the antecedent about, it
will be understood that the particular value forms another aspect.
It will be Further understood that the endpoints of each of the
ranges are significant both in relation to the other endpoint, and
independently of the other endpoint.
[0072] When the terms prevent, preventing, and prevention are used
herein in connection with a given treatment for a given condition
(e.g., preventing pneumococcal infection), they mean that the
treated patient either does not develop a clinically observable
level of the condition at all, or develops it more slowly and/or to
a lesser degree than he/she would have absent the treatment. These
terms are not limited solely to a situation in which the patient
experiences no aspect of the condition whatsoever. For example, a
treatment will be said to have prevented the condition if it is
given during exposure of a patient to a stimulus that would have
been expected to produce a given manifestation of the condition,
and results in the patient's experiencing fewer and/or milder
symptoms of the condition than otherwise expected. A treatment can
prevent infection by resulting in the patient's displaying only
mild overt symptoms of the infection; it does not imply that there
must have been no penetration of any cell by the infecting
microorganism.
[0073] Similarly, reduce, reducing, and reduction as used herein in
connection with the risk of infection with a given treatment (e.g.,
reducing the risk of a pneumococcal infection) refers to a subject
developing an infection more slowly or to a lesser degree as
compared to a control or basal level of developing an infection in
the absence of a treatment (e.g., administration of an immunogenic
polypeptide). A reduction in the risk of infection may result the
patient's displaying only mild overt symptoms of the infection or
delayed symptoms of infection; it does not imply that there must
have been no penetration of any cell by the infecting
microorganism.
[0074] It is to be understood that the disclosed method and
compositions are not limited to specific synthetic methods,
specific analytical techniques, or to particular reagents unless
otherwise specified, and, as such, may vary. It is also to be
understood that the terminology used herein is for the purpose of
describing particular embodiments only and is not intended to be
limiting.
[0075] A number of embodiments of the invention have been
described. Nevertheless, it will be understood that various
modifications may be made. Furthermore, when one characteristic or
step is described it can be combined with any other characteristic
or step herein even if the combination is not explicitly stated.
Accordingly, other embodiments are within the scope of the
claims.
EXAMPLES
Example 1
PcpA Elicits Protection Against Lung Infection and Fatal Sepsis
[0076] Materials and Methods.
[0077] Bacterial strains, medium, and growth conditions. S.
pneumoniae strains TIGR4 and EF3030, and their derivatives, were
used in this study. Pneumococci were grown at 37.degree. C. in
Todd-Hewitt broth with 0.5% yeast extract (THY) or on blood agar
plates unless otherwise indicated. When appropriate, erythromycin
was added to the medium at a concentration of 0.3 .mu.g/ml.
Clinical isolates of S. pneumoniae (Table 2) and isolates of major
clonal groups (Table 3) were used.
TABLE-US-00002 TABLE 2 Clinical Isolates of Streptococcus
pneumoniae Capsular PspA Strain type family Origin Reference R6
Non- 1 New York (Belanger et al., J. Bacteriol. encapsulated 186:
8164-71 (2004); variant of Ottolenghi and Hotchkiss, D39 (type 2)
Science 132: 1257-8 (1960) TIGR4* 4 2 Norway Ren et al., Infect.
Immun. 71: 75-85 (2003); Roach et al., PNAS 102: 9577-82 (2005)
BG12730* 6 2/3 Gambia Shaper et al., Infect. Immun. 72: 5031-40
(2004) BG10752* 9 1 Alabama This Study TJ0893* 14 2 Mississippi Wu
et al., J. Infect. Dis. 175: 839-46 (1997) V175* 18 2 Tennessee
Robinson et al., J. Infect. Dis. 183: 1501-7 (2001) L82013* 19 2
Alaska Briles et al., Infect. Immun. 188: 339-48 (2003) EF3030* 19F
1 Sweden Briles et al., Infect. Immun. 188: 339-48 (2003); Briles
et al., Infect. Immun. 73: 6945-51 (2005); Johnston et al., Infect.
Immun. 74: 1171-80 (2006) EF9303* 23F Unknown Sweden Wu et al.,
Microb. Pathog. 23: 127-37 (1997) L82016* 6B 1 U.S.A. Briles et
al., Infect. Immun. 60: 111-6 (1992); Briles et al., Infect. Immun.
188: 339-48 (2003) D-1091B* 23 1 Unknown This Study *clinical
strains that are not separated by more than 10 passages from the
original patient isolate. R6 was derived from strain D39, which was
a patient isolate in the 1920's.
TABLE-US-00003 TABLE 3 Streptococcus pneumoniae of major clonal
groups Capsular Strain type Origin Characteristics Reference MA-14
14 UK Worldwide Erm.sup.r clone; (1) MLST sequence type 9 MB-23F
23F UK Unknown disease; MLST (1) sequence type 81 MC-6B 6B Spain
Unknown disease; MLST (3, 4) sequence type 90 MD-6B 6B Alaska
Unknown disease; MLST (2) sequence type 138 ME-19 19 Tennessee
Carriage clone; MLST (2) sequence type 236 MF-6A 6A Tennessee
Carriage clone; Unknown (2) MLST sequence type MG-1 1 UK Major
invasive clone; (1) MLST sequence type 227 MI-7F 7F Norway Major
invasive clone; (1) MLST sequence type 191 MJ-35 35 Tennessee
Carriage clone; MLST (2) sequence type 65 MK-22 22 Tennessee Major
invasive clone; (2) Unknown MLST sequence type ML-11 11 Tennessee
Carriage clone; MLST (2) sequence type 62 MM-14 14 Tennessee Major
invasive clone; (2) MLST sequence type 124 MN-23F 23 Tennessee
Carriage clone; MLST (2) sequence type 37 (1) Enright, M. C., and
B. G. Spratt. 1998. A multilocus sequence typing scheme for
Streptococcus pneumoniae: identification of clones associated with
serious invasive disease. Microbiology 144: 3049-60. (2) Robinson,
D. A., K. M. Edwards, K. B. Waites, D. E. Briles, M. J. Crain, and
S. K. Hollingshead. 2001. Clones of Streptococcus pneumoniae
Isolated from Nasopharyngeal Carriage and Invasive Disease in Young
Children in Central Tennessee. J Infect Dis 183: 1501-7. (3)
Hakenbeck, R., T. Briese, L. Chalkley, H. Ellerbrok, R.
Kalliokoski, C. Latorre, M. Leinonen, and C. Martin. 1991.
Antigenic variation of penicillin-binding proteins from
penicillin-resistant clinical strains of Streptococcus pneumoniae.
J Infect Dis 164: 313-319. (4) Hakenbeck, R., T. Briese, L.
Chalkley, H. Ellerbrok, R. Kalliokoski, C. Latorre, M. Leinonen,
and C. Martin. 1991. Variability of penicillin-binding proteins
from penicillin-sensitive Streptococcus pneumoniae. J Infect Dis
164: 307-312.
[0078] The clinical strains used in these studies were isolated
within the last 25 years. To examine the possible diversity of
PcpA, isolates were selected from the group of strains utilized in
the Streptococcus pneumonia Genome Diversity Project
(http://genome.microbio.uab.edu/strep/info).
[0079] During strain construction, plasmids were maintained in
Escherichia coli TOP10 cells (Invitrogen, Carlsbad, Calif.) grown
in Luria-Bertani (LB) broth or LB plates with 1.5% agar. Ampicillin
(50 .mu.g/ml) for pCR2.1, pCR4 and pET-20b-based plasmids or
erythromycin (400 .mu.g/ml) for pJY4164-based plasmids was added to
the growth medium.
[0080] THY medium was used for growth of bacteria in high manganese
medium. For growth in low manganese conditions, a manganese
depleted form of THY was prepared. THY medium was prepared
according to the manufacturer's directions, with Chelex-100 (2%
w/v) (Sigma Aldrich, St. Louis, Mo.) added prior to autoclaving.
After autoclaving, the THY/Chelex mixture was stirred overnight at
room temperature, followed by filter sterilization. ZnCl.sub.2,
MgCl.sub.2, CaCl.sub.2, and FeSO.sub.4 were added to concentrations
of 1 mM each, and MnSO.sub.4 was add to a concentration of 0.1
.mu.M prior to use. Growth was monitored by optical density at 600
nm.
[0081] Strain construction. The E. Coli strains, plasmids, and
primers used in this study are listed (Table 4). Mutagenesis was
used to inactivate pcpA in the parental strains TIGR4 and EF3030.
The construction of mutant strains was previously carried out and
described (Johnston, et al., Infect. Immun. 74:1171-80 (2006)).
TABLE-US-00004 TABLE 4 Additional bacterial strains, and plasmids
used in this study Strain, plasmid, or primer Relevant
characteristics or sequence and gene Reference Strains S.
pneumoniae JEN7 TIGR4 psaR::Erm (pcpA constituative mutant)
Johnston, et al., Infect. Immun. 74: 1171-80 (2006) Jen11 TIGR4
pcpA::Erm Johnston, et al., Infect. Immun. 74: 1171-80 (2006) E.
coli TOP10 General cloning strain Invitrogen, Carlsbad, CA Rosetta
(DE3) pLysS Expression strain Novagen, Madison, WI Plasmids pCR2.1
3.9 kb, Amp.sup.r, Kan.sup.r Invitrogen, Carlsbad, CA pCR4 3.9 kb,
Amp.sup.r, Kan.sup.r Invitrogen, Carlsbad, CA pET-20b 3.7 kb,
Amp.sup.r, C-term his-tag Novagen, Madison, WI pDG-1 pCR4 with pcpA
fragmnet; Amp.sup.r This study pJM-1 pET-20b with pcpA fragment;
Amp.sup.r This study pJJ035 pCR2.1 with 412 bp internal pcpA
fragment: This study Amp.sup.r Primers.sup.a DTG-16
cgcggatccATATGTCCCTAATGAACC (SEQ This study ID NO: 39); pcpA F
DTG-12 gcgctcgagTTCCTTTAATGAATCTAAGACGC This study
CACTTAGGAAGAAGGAC (SEQ ID NO: 40); pcpA R JWJ28 AAC TGT TCA AGT GGG
TAA TGG (SEQ Johnston, et al., Infect. ID NO: 48); pcpA F Immun.
74: 1171-80 (2006) JWJ29 TGA ACT TGA GGA AAA GGT TAG C (SEQ
Johnston, et al., Infect. ID NO: 49); pcpA R Immun. 74: 1171-80
(2006) BGP1 ATGAAAAAACTACAATATTATCATTAAC This study TACAGCTGCG (SEQ
ID NO: 50); pcpA F BGP2 CCATAAACCTTTGTCTTTAACCCAACCA This study
ACTAC (SEQ ID NO: 51); pcpA R .sup.aPrimers were based on the
complete genome sequence of S. pneumoniae TIGR4 (2). Lowercase
denotes mismatches used to create restriction endonuclease sites.
All sequences are expressed 5' to 3'.
[0082] Recombinant PcpA expression and purification. The strains,
plasmids, and primers used in this study are listed in Table 2.
Primers DTG-16 (5'-CGCGGATCCATATGTCCCTAATGAACC-3' (SEQ ID NO:39))
and DTG-12 (5'-GCGCTCGAGTTCCTTTAATGAATCTAAGACGCCACTTAGGAAGAAGGA
C-3' (SEQ ID NO:40)) were designed to amplify a 1126 bp fragment of
pcpA in strain TIGR4. The primers contain engineered restriction
endonuclease sites, BamHI and XhoI respectively. Reactions were
carried out for 30 cycles in a total volume of 50 .mu.l in a
cocktail containing 3.0 mM MgCl.sub.2, 125 .mu.M dNTPs, 50 picomole
of each primer, and 2.5 units of Taq DNA Polymerase. The cycle was
94.degree. C., 1 min.; 55.degree. C., 1 min; 72.degree. C., 5
minutes. This amplified gene fragment was initially cloned into
pTOPO4 (Invitrogen, Inc., Carlsbad, Calif.) by a T-tailed method
forming plasmid pLMG.
[0083] This fragment was cloned into pCR4 with the TOPO TA cloning
kit (Invitrogen, Carlsbad, Calif.). Purified plasmids were screened
by endonuclease digestion with BamHI and XhoI (Promega, Madison,
Wis.). Agarose gel electrophoresis, PCR analysis, and DNA
sequencing were all used to confirm insertion of the pcpA fragment
in the resulting plasmid, pDG-1. The insert from pDG-1 was
subcloned into the pET-20b expression vector (Novagen, Madison,
Wis.). The resulting plasmid, pJM-1, was transformed into the E.
coli strain RosettaBlue (DE3) pLysS (Novagen, Madison, Wis.) for
protein production. This strain contains a chromosomal copy of the
T7 promoter under control of the inducible UV5 promoter. Upon IPTG
induction a truncated protein, containing amino acids 19-391, was
expressed. The over-expressed truncated protein was purified using
the Novagen HIS-BIND.RTM. Purification Kit (Novagen, Madison,
Wis.), which utilized a C-carboxy terminal histidine tag to
facilitate purification. Subsequent SDS-PAGE analysis with Comassie
Blue staining yielded a single band of approximately 41-kDa.
[0084] Below is the complete sequence of the rPcpA protein that has
been cloned and expressed. Underlined portions are from the cloning
vector.
TABLE-US-00005 (SEQ ID NO: 41)
MDIGNSDPYVPNEPILADTPSSEVIKETKVGSIIQQNNIKYKVLTVEGNI
GTVQVGNGVTPVEFEAGQDGKPFTIPTKITVGDKVFTVTEVASQAFSYYP
DETGRIVYYPSSITIPSSIKKIQKKGFHGSKAKTIIFDKGSQLEKIEDRA
FDFSELEEIELPASLEYIGTSAFSFSQKLKKLTFSSSSKLELISHEAFAN
LSNLEKLTLPKSVKTLGSNLFRLTTSLKHVDVEEGNESFASVDGVLFSKD
KTQLIYYPSQKNDESYKTPKETKELASYSFNKNSYLKKLELNEGLEKIGT
FAFADAIKLEEISLPNSLETIERLAFYGNLELKELILPNNVKNFGKHVMN
GLPKLKSLTIGNNINSLPSFFLSGVLDSLKELEHHHHHH
[0085] Anti-PcpA polyclonal antibody production. Purified rPcpA was
used to immunize a New Zealand White Rabbit (Myrtle's Rabbity,
Thompson Station, Tenn.) rabbit subcutaneously to obtain anti-PcpA
polyclonal serum. The rabbit was injected subcutaneously with 100
.mu.g of rPcpA in 1 ml of Freund's complete adjuvant, 2 ml total
volume. A second boost, with 100 .mu.g of rPcpA in Freund's
incomplete adjuvant, was given 2 weeks later and a third boost of
100 .mu.g of PcpA in Freund's incomplete adjuvant was given 2 weeks
after the second boost. Two weeks following the final boost the
rabbit was bled by cardiac puncture, under anesthesia. The blood
was allowed to clot, and serum was obtained by centrifugation and
stored at -80.degree. C.
[0086] PCR confirmation of pcpA in S. pneumoniae strains. The
presence or absence of pcpA in various S. pneumoniae strains was
checked using PCR primer pair BGP-1 and BGP-2. The primer pair was
designed to amplify a 1416 bp N-terminal fragment of pcpA in strain
TIGR4. The PCR products were then separated on a T.A.E. agarose
gel, stained with ethidium bromide, and examined for the correct
size amplified band.
[0087] S. pneumoniae cell fractionation. Protoplasts were produced
with the method described by Yother and White (Yother and White, J.
Bacteriol. 176:2976-85 (1994)), with slight modification. Log-phase
cells, grown in MTHY, were pelleted and washed in PBS. The cells
were then resuspended in 0.5 ml of 2% choline chloride and the tube
inverted several times. The cells were then pelleted and the
supernatant drawn off and stored at -20.degree. C. (choline elution
fraction). Cells were pelleted and washed once with 300 .mu.l of
protoplast buffer (20% sucrose, 5 mM Tris [pH 7.4], 2.5 mM
MgSO.sub.4). The pellet was then resuspended in 1 ml protoplast
buffer, and Mutanolysin (Sigma Aldrich, St. Louis, Mo.) was then
added at 5 U per ml of culture pelleted. The suspension was
incubated overnight at room temperature. Cells were pelleted by
centrifugation at 6000 rpm for 10 min, supernatant is stored at
-20.degree. C. (Cell Wall Fraction). The protoplast were then
washed in 1 ml of protoplast buffer. The formation of protoplasts
was confirmed by microscopic examination. The protoplast were
pelleted and lysed in 0.3-1 ml of dH.sub.2O, this is stored at
-20.degree. C. (Cell Membrane/Cytosolic Fraction). Samples of each
fraction are examined for the presence of PcpA by Western blot
analysis.
[0088] Antibody staining of S. pneumoniae. Mid-log-phase cells,
OD.sub.6000.6, grown in high or low manganese medium, were
pelleted, washed with PBS, resuspended in PBS with 1% bovine serum
albumin (PBSB), and incubated at room temperature 20 min. Cells
were pelleted and resuspended in PBSB or anti-PcpA serum diluted
1:100 in PBSB and incubated at 37.degree. C. for 30 min. Incubation
was followed by two washes with PBS. Cells were then incubated with
goat anti-rabbit immunoglobulin G (heavy and light
chains)-fluorescein isothiocyanate (Southern Biotechnology
Associates, Inc., Birmingham, Ala.) diluted in PBSB at 4.degree. C.
for 30 min. The cells were then washed twice with PBS and
resuspended in 4% formaldehyde in PBS containing 0.01 mM of the
lipophylic membrane dye TMA-DPH (Invitrogen, Carlsbad, Calif.).
Bacterial cells were then inspected by epifluorescence using the
Olympus IX 70 microscope.
[0089] Western blot. Bacterial cultures were grown in THY and MTHY
to mid-log phase, OD.sub.6000.6. Equivalent amounts of each strain
were washed twice with phosphate-buffered saline (PBS), resuspended
in PBS with sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer, and boiled for 5 min.
Samples and a pre-stained protein standard (Invitrogen, Carlsbad,
Calif.) were loaded onto a NuPAGE 10% Bis-Tris gel (Invitrogen,
Carlsbad, Calif.) and separated by electrophoresis in
morpholinoethanesulfonic acid (MES)-SDS running buffer (Invitrogen,
Carlsbad, Calif.) in accordance to the manufacturer's instructions.
Proteins were then transferred to a nitrocellulose membrane with
the Trans-Blot SD semidry transfer cell (Bio-Rad, Hercules,
Calif.). The blot was probed with anti-PcpA polyclonal antibody
diluted 1:1000 in PBSB. Goat anti-rabbit immunoglobulin G (heavy
and light chains)-alkaline phosphatase and streptavidin-alkaline
phosphatase (Southern Biotechnology Associates, Inc., Birmingham,
Ala.) were used as the secondary antibody. Colorimetric detection
was performed with Sigma Fast
nitrobluetetrazolium-5-bromo-4-chloro-3-indolylphosphate (NBT-BCIP)
tablets (Sigma Aldrich, Switzerland).
[0090] Systemic immunization of nice. 6-8 week old CBA/CaHNBtkxid/J
(CBA/N) mice (JacksonLabs, Bar Harbor, Me.) were initially injected
subcutaneously with 10 .mu.g of rPcpA with 2 .mu.g of Aluminum
hydroxide as an adjuvant, 200 .mu.l total volume. A second boost
with 10 .mu.g of rPcpA with Aluminum hydroxide was given 2 weeks
later. A third boost containing 10 .mu.g of rPcpA without Aluminum
hydroxide was given 2 weeks following. The mice were then allowed
to rest 2 weeks prior to challenge with S. pneumoniae. Mice were
bled 24 hrs prior to infection.
[0091] Murine model of sepsis. The virulence of pneumococci was
examined in a systemic model of infection previously described
(Coats, et al., Vaccine 23:4257-62 (2005); Ren et al., Infect.
Immun. 71:75-85 (2003)). 6-8 week old CBA/N mice were injected
intravenously with 300 CFUs of bacteria diluted in lactated
ringers. Mice were monitored for 21 days. When they become
unresponsive to touch and their body temperature decreased to below
normal they were scored as moribund and the date and time were
recorded. All moribund mice were euthanized with CO.sub.2
narcosis.
[0092] Murine model of pneumonia. Lung infections were performed as
previously described (Balachandran et al., Infect. Immun.
70:2526-34 (2002); Briles et al., J. Infect. Dis. 188:339-48
(2003); Takashima et al., Infect. Immun. 65:257-260 (1997)). 6-8
week old CBA/N mice were anesthetized with Isoflurane (MinRAD,
Buffalo, N.Y.), and suspensions of 40 .mu.l of lactated ringers
solution containing 5.times.10.sup.6 bacteria were introduced into
the nares of the mice to induce aspiration pneumonia. After 7 days
the mice were sacrificed. The nasal cavities of sacrificed mice
were washed with 50 .mu.l of lactated ringers, as previously
described (Wu et al., J Infect. Dis. 175:839-46 (997)). The nasal
wash was serially diluted and plated onto blood agar with
gentamicin (4 .mu.g/ml). The lungs were harvested and placed into 2
ml of lactated ringers in a stomacher bag, homogenized, serially
diluted, and plated onto blood agar with gentamicin in serial
3-fold dilutions.
[0093] Murine model of nasopharyngeal colonization: Intranasal
inoculations were performed as previously described (Balachandran
et al., Infect. Immun. 70:2526-34 (2002); Wu et al., J. Infect.
Dis. 175:839-46 (1997)). 6-8 week old CBA/N mice were infected
intranasally with 10.sup.6 bacteria in 10 .mu.l of lactated
Ringer's solution without anesthesia. Infected mice were then
sacrificed, and their nasal cavities were washed with 50 .mu.l of
Ringer's solution. The nasal washes were serially diluted and
plated on blood agar with gentamicin. Visible counts from blood
agar plates were determined after overnight incubation at
37.degree. C. in candle jars.
[0094] Statistical analysis. Statistically analysis was carried out
using Instat (GraphPad Software Inc., San Diego, Calif.).
Comparisons of time to moribund or numbers of recovered CFU between
the control and experimental groups were conducted using the
Mann-Whitney two sample rank test. P-values less than 0.05 were
considered to be statistically significant.
Results
[0095] pcpA is present in clinically relevant strains of S.
pneumoniae. The presence of pcpA was examined by PCR, with primers
(BGP1 and BGP2) spanning the LRR region of the pcpA. Each of the 23
strains examined (Tables 2 and 3) yielded a roughly 1500-bp
fragment. Eight of these strains are clinical strains isolated
within the last 25 years that are representative strains of the
seven common capsular types covered by the 7-valent conjugate
vaccine (FIG. 1). The remaining 12 strains are a set of S.
pneumoniae that were selected from a set of strains assembled as
part of the Genome Diversity Project
(http://genome.microbio.uab.edu/strep/info/) which includes a set
of strains chosen to span the breadth of diversity in S.
pneumoniae. These 12 strains were selected as highly divergent
based on MLST data. Four strains were from patients with serious
invasive disease, five were from asymptomatic carriage, for 2
strains disease/colonization was not know, and one strain was from
a worldwide antibiotic resistant clone. These strains represent 12
different capsule types from different world regions.
[0096] To test for expression of PcpA in all strains they were
grown in low (.ltoreq.0.1 .mu.M) manganese. Total cellular protein
samples were prepared from mid-log phase cells cultured in the low
manganese medium. All strains listed in (Tables 2 and 3) were
examined, but only those representing capsular types included in
the heptavalent vaccine are depicted (FIG. 2). Total cellular
protein samples were separated by SDS-PAGE and transferred to
nitrocellulose. The blot was probed with anti-PcpA polyclonal
antiserum, identifying a band of approximately 62-kDa in each of
these wild-type strains of capsulare serotypes 4, 6, 9, 14, 18, 19,
23 (FIG. 2). This 62-kDa band was absent in the pcpA-inactivated
mutant JEN11 but was present in seven representative strains. Total
cellular protein samples were also prepared from strains grown in
high manganese medium for the same strains, but no bands were
identified with the anti-PcpA antiserum. The PCR analysis in
combination with the Western blot data, demonstrated that pcpA is
present in all S. pneumoniae strains listed in Tables 2 and 3.
[0097] PcpA is exposed on the surface of S. pneumoniae under low
manganese conditions. Studies have shown that through the action of
the regulator PsaR, manganese controls the transcription of the
pcpA gene (Johnston et al., Infect. Immun. 74:1171-80 (2006)). As
described herein, manganese dependent regulation directly affects
the presence of PcpA on surface of S. pneumoniae and surface PcpA
is accessible to antibody even on encapsulated pneumococci.
[0098] Cell fractionation was performed to determine if PcpA was
associated with the cell wall or cell membrane/cytosol of S.
pneumonia. Western blot analysis of these cellular fractions
revealed that PcpA was present predominantly in the cell wall of S.
pneumoniae, in bacteria grown in low manganese medium. A small
fraction of the PcpA was associated with the cell membrane/cytosol,
and probably represents PcpA yet to be exported to the surface of
the bacteria.
[0099] In addition to the cell fractionation, log-phase cells from
wild type S. pneumoniae strain TIGR4 were grown in high or low
manganese medium, stained with anti-PcpA polyclonal antiserum
followed by fluorescein isothiocyanate (FITC)-conjugated
anti-rabbit immunoglobulin. Specifically, TIGR4 was cultured in
high or low Mn2+ medium until mid-log phase. Bacteria were
incubated with anti-PcpA rabbit serum, followed by incubation with
FITC-conjugated anti-rabbit Ig antibodies. Cells were then fixed in
4% formaldehyde containing the membrane dye TMA-DPH. The labeled
bacteria were then examined by immunofluorescence microscopy. The
antibodies to PcpA were able to mediate staining of the bacteria
grown in low manganese, but not those grown in high manganese.
[0100] These results indicate that PcpA is surface exposed on
wild-type S. pneumoniae cultured under low manganese conditions in
vitro. This indicates that PcpA is expressed and surfaced exposed
on bacteria infecting low manganese sites inside the host, such as
the lungs and blood. This exposure of PcpA facilitates PcpA-ligand
interactions between the bacterium and the host epithelium during
infection. These results also indicate that regulation of PcpA
production by manganese concentration is generalizable to most
pneumococci.
[0101] Immunization with rPcpA elicits antibody and provides
protection against lung and systemic injection, but does not
significantly affect nasopharyngeal colonization. Mice were
immunized with rPcpA with aluminum hydroxide or received aluminum
hydroxide alone, prior to use in infection studies. Total Ig(H+L)
was quantified for both groups of mice by ELISA. The geometric mean
level of antibody specific PcpA in the serum of the immunized mice
was 0.465 (.+-.0.119) .mu.g/ml, versus a mean of 0.002 (.+-.0.002)
.mu.g/ml for mice receiving the adjuvant alone, (.+-.SEM). This
indicates the route of immunization was successful at eliciting an
immune response to rPcpA.
[0102] To see if the immunization protected mice from pneumonia,
the immunized and alum-only mice were lightly anesthetized and
inoculated in the nares with 5.times.10.sup.6 CFU of strain EF3030.
This procedure resulted in focal pneumonia without bacteremia.
Protection in this model can thus be associated with pneumonia per
se and not sepsis in general. Seven days post infection all mice
were sacrificed. Bacterial counts were determined from homogenized
lung tissue and nasal wash. Based on the median CFU recovered,
there were less than 1/100 as many pneumococci recovered from the
lung homogenates of mice immunized with rPcpA versus those
receiving adjuvant alone (FIG. 3A)(P=0.002). These results indicate
that immunization with rPcpA is able to elicit protection against
pulmonary infection with S. pneumoniae. There was no significant
difference in the bacterial counts recovered from nasal washes of
mice immunized with rPcpA versus those receiving adjuvant alone
(FIG. 3B). Recombinant PcpA .DELTA.SP.DELTA.CBD (rPcpA
.DELTA.SP.DELTA.CBD), described in detail below, from S. pneumoniae
strain serotype 6 also protected against lung infection but not
colonization in a mouse model of pneumonia.
[0103] Next it was determined whether subcutaneous immunization
would confer protection against focal lung infection with other
strains of S. pneumoniae (TJ0893, serotype 14; EF9303, serotype
23F; and L82016, serotype 6B). Subcutaneous immunization with rPcpA
elicited significant protection against each strain compared to
mice receiving immunizations of just the adjuvant alone (FIG.
5).
[0104] Expression of PcpA is not required for optimal nasal
colonization. Since immunization did not affect the number of
bacteria recovered from the nasal washes of mice used for the
pneumonia model, the effect of pcpA inactivation was examined in a
model of nasopharyngeal carriage. This model allowed a direct view
of any effects of PcpA on nasal carriage, as opposed to the
indirect observations gathered from the nasal washes of mice in the
pneumonia model. Mice were inoculated without prior anesthesia with
10.sup.6 CFU of either strain EF3030 or its pcpA-inactivated mutant
JEN18. Seven days post infection the mice were sacrificed and nasal
washes were collected and plated to detect pneumococci. There was
no significant difference in the number of bacteria recovered from
the nasal washes of mice inoculated with either EF3030 or JEN18
(FIG. 5).
[0105] The failure of either the presence of an intact pcpA gene or
subcutaneous immunization with rPcpA to have an effect on numbers
of pneumococci recovered in the nasal washes of mice is consistent
with the fact that the manganese concentration in the nasopharynx
(.gtoreq.36 .mu.M) is high enough to suppress pcpA transcription.
Under these conditions pcpA transcription would be repressed, by
psaR, in the nasopharynx. Thus, immunity to PcpA would be expected
to have little effect on bacteria in this host site.
[0106] PcpA and immunity to PcpA effects virulence in the murine
model of systemic infection. To evaluate the ability of immunity to
PcpA to protect against sepsis, CBA/N mice were subcutaneously
immunized with PcpA in aluminum hydroxide or aluminum hydroxide
alone as a control and challenged intravenously with capsular type
4, TIGR4 S. pneumoniae. This strain was used rather than EF3030
since this strain can readily cause bacteremia and sepsis in mice.
The immunized animals were injected IV with 300 CFU of TIGR4 strain
S. pneumoniae. Survival was monitored for 21 days. Mice receiving
rPcpA immunizations had a median time to become moribund that was
extended by 43.5 hours compared to mice receiving adjuvant alone
(FIG. 6). Twenty six percent of mice immunized with rPcpA lived,
whereas no mice immunized with aluminum hydroxide alone lived; this
difference in survival was statistically significant (P=0.007).
[0107] Effect of inactivation of pcpA on the ability of pneumococci
to cause mice to become moribund following intravenous inoculation.
Inactivation of pcpA results in reduced virulence in the murine
model of pneumonia and in a lung-sepsis model. As described herein,
the effect of pcpA inactivation on systemic infection following
intravenous challenge was examined by infecting naive mice with 300
CFU of either TIGR4 or its pcpA inactivated mutant JEN11. The
median time to become moribund for mice infected with the
pcpA.sup.- mutant was extended by 31.5 hours (P=0.0299) compared to
those infected with wild-type bacteria (FIG. 7). This demonstrates
that there is a role for PcpA in the ability of S. pneumoniae to
cause systemic diseases.
Example 2
Mucosal Immunization with PcpA Protects Against Lung Infection
[0108] As shown in FIG. 8, mucosal immunization with PcpA protects
against pulmonary infection with strain EF3030. CBA/N mice were
immunized intranasally with 5 .mu.g of PcpA plus cholera toxin B
sub-unit (CTB) as the adjuvant. Post-immunization mice were bled
and then challenged intranasally with 5.times.10.sup.6 CFU of
strain EF3030. FIG. 8 shows log CFU of bacteria in lung homogenate
at 7 days post-infection.
[0109] Mucosal immunization protection was observed to be slightly
better than with immunization. These data and Example 1 indicate
that protection against pneumonia and sepsis can be conferred using
at least mucosal or subcutaneous routes of administration. Mucosal
immunization with PcpA does not protect against nasal colonization
with this strain. This is expected since PcpA is not expressed
during colonization.
Example 3
Antibody Elicited by Subcutaneous or Intranasal Immunization with
PcpA
[0110] Sera obtained from mice immunized with PcpA were examined
for the level of antibody to PcpA. CBA/N mice were immunized either
subcutaneously (SC) with aluminum hydroxide or cholera toxin B
subunit (CTB) as the adjuvant on days 0 and 14, and with PcpA alone
on day 21. On day 35 mice were bled and the antibody levels in the
serum were determined by using as a standard the OD observed with a
known concentrations of PspA antibodies reacting with PspA-coated
microtitration plates. As controls, additional groups of mice were
immunized with diluent and adjuvant alone. A 1.3-fold higher IgG
antibody response was observed with SC rather than intranasal (IN)
immunization (Table 5).
TABLE-US-00006 TABLE 5 Antibodies to PcpA in mice immunized with
PcpA rPcpA Route of Ig(H + L) IgG1 IgG2a IgG2b IgA Admin. Group
Mean .mu.g/ml (.+-.SEM) S.C. rPcpA + 0.465 (0.159) 1.768 (0.378)
0.123 (0.041) 0.125 (0.048) <0.001 Adjuvant (n = 10) S.C.
Adjuvant 0.002 (0.002) 0.007 (0.007) <0.001 0.002 (0.001)
<0.001 alone (n = 10) I.N. rPcpA + 0.356 (0.159) 0.151 (0.085)
0.118 (0.057) 0.093 (0.033) <0.001 Adjuvant (n = 10) I.N.
Adjuvant <0.001 <0.001 <0.001 <0.001 <0.001 alone (n
= 10)
[0111] As is common with this type of assay, the amounts of the
subclasses did not add up to the amount of total Ig. This is an
indication that anti-IgG serum does not recognize all IgG
subclasses equally.
Example 4
PcpA is Necessary for Adherence to Lung Cells
[0112] PcpA is necessary for adherence to the A549 cell line of
transformed lung epithelial cells (FIG. 9) but not to the
Detroit562 line of transformed human nasal epithelial cell (FIG.
10). It was observed that adherence to the A549 lung epithelial
cells also required that the pneumococci be grown in low Mn.sup.2+
so that they would produce PcpA. The pneumococci for these studies
were grown in Todd-Hewitt and Yeast medium (high Mn.sup.2+) or
Todd-Hewitt and Yeast Medium that had been passed over Chelex-100
(Sigma) and reconstituted with 0.1 .mu.m MnSO.sub.4 and 1 mM
ZnCl.sub.2, MgCl.sub.2, CaCl.sub.2, and FeSO.sub.4. (low Mn.sup.2+)
(Briles et al., J. Infect. Dis. 188:339-48 (2003)). The Detroit 562
or A549 cells monolayers were incubated for 150 minutes with
10.sup.6 CFU of TIGR4 (pcpA+) or JEN11 (pcpA- TIGR4 strain). The
epithelial cells with adherent bacteria were washed and lysed with
0.5% Tween 20. The numbers of pneumococci in the lysate were
determined by quantitative plating on blood agar plates.
[0113] Adherence of pneumococci to A549 cells is inhibited with
antibody to PcpA (FIG. 11). These data demonstrate PcpA-dependent
adherence of pneumococci to lung epithelial cells.
Example 5
Passive Protection Model
[0114] Based on the ability of active immunization with PcpA to
elicit protection against lung infection, it was determined whether
antibody to PcpA would be able to passively protect mice from lung
infection. However, passive protection has not yet been observed in
a pneumonia model. In a second passive immunization study, passive
protection against IV sepsis with the TIGR4 strain was determined
using immune rabbit sera to PcpA. It was observed that the highest
concentration of sera tested (1/10) was able to protect two of mice
from death (FIG. 12). A non-immune serum was not able to protect at
the same concentration. These data suggest that passive
immunization can protect against TIGR4 strain, which can be a
difficult strain to protect against (Roche et al., Infect. Immun.
71:4498-505 (2003)).
Example 6
Protection by PcpA and Pneumolysin
[0115] Pneumolysin (Ply) is another protein that can elicit some
protection against lung infection (Briles et al., J. Infect. Dis.
188:339-48 (2003)). Since pneumolysin and PcpA are both candidates
for use in protein-based pneumococcal vaccines, it was determined
whether the two proteins produce better protection against lung
infection when both are used as immunogens than when either one is
used alone. Mice were immunized three times with 5 .mu.g of PcpA, 5
.mu.g pneumolysin, or 5 .mu.g of PcpA plus 5 .mu.g of pneumolysin.
The first two injections were with alum and the third injections
were with protein alone. The pneumolysin used here was wild-type
pneumolysin. FIG. 13 shows that pneumolysin elicits similar
protection against lung infection to that elicited by PcpA. The
combination of PcpA and pneumolysin was significantly more
protective than pneumolysin alone. These data indicate that
protection can be conferred using both PcpA and pneumolysin.
Example 7
Cross-Protection Against Other Pneumococci
[0116] To determine whether PcpA elicits cross protection, strains
in addition to those described in Examples 1-2 can be tested using
the methods described above. For studies of sepsis, strains such as
WU2, A66, BG7322, EF6796, D39 in addition to TIGR4 are tested.
These strains are of capsular types 3, 3, 6B, 6A, and 2. To examine
lung infection, strains that work well in a mouse model of focal
lung infection are used. These strains include EF9309, TG0893,
L82016, BG7322 and EF6796. These are capsular types 23F, 14, 6B,
6B, and 6A.
Example 8
Cloning and Expression of Recombinant PcpA from Streptococcus
pneumoniae Serotype 6
[0117] A fragment of the pcpA gene from Streptococcus pneumoniae
serotype 6 strain, 14453, ATCC Designation No. 55987 was cloned as
follows. The pcpA gene lacking the portion encoding the PcpA
C-terminal choline-binding domain (CBD) repeats and lacking the
portion encoding the native signal peptide (SP) sequence was cloned
into pET-30a (Novagen, Inc., Madison, Wis.) between the NdeI and
XhoI cloning sites as shown in FIG. 14. An internal gene fragment
of the pcpA gene (.DELTA.SP.DELTA.CBD1335 bp) was amplified by
polymerase chain reaction (PCR) from Streptococcus pneumoniae
serotype 6 strain chromosomal DNA using the oligonucleotide primers
5'-TAGCCTCGAGTTAACCTTTGTCTTTAACCCAACCAACTACTCCCTGATTA G-3 (SEQ ID
NO:43) and 5'-CTAATGAACCACATATGGCAGATACTCCTAGTTCGGAAGTAATC-3' (SEQ
ID NO:44). PCR reactions were carried out as described in Example
1. The PCR primers incorporated the restriction endonuclease sites
NdeI and XhoI. The resulting 1335 base pair fragment encoding PcpA
.DELTA.SP.DELTA.CBD, contained the NdeI and XhoI sites at either
end. The amplified fragment was gel purified and digested with NdeI
and XhoI, the pcpA gene fragment was then ligated between NdeI and
XhoI sites of the pET-30a vector (Novagen, Inc., Madison, Wis.)
with a strong T7 promoter and translation signals (FIG. 14). DNA
sequencing confirmed that the recombinant plasmid pJMS87 contained
the pcpA gene fragment .DELTA.SP.DELTA.CBD1335 bp. Plasmid pJMS87
was transformed into the E. coli strain BL21 (DE3) for protein
production. This E. coli strain upon induction with IPTG, expressed
the PcpA protein lacking the native signal peptide (.DELTA.SP) and
the c-terminal choline-binding domain (.DELTA.CBD). The expressed
protein was identified by SDS-PAGE analysis.
[0118] The sequence of the rPcpA protein (also known as PcpA
.DELTA.SP.DELTA.CBD) is as follows. The underlined residue (M) is
from the cloning vector.
TABLE-US-00007 (SEQ ID NO: 45) MADTPSSEVI KETKVGSIIQ QNNIKYKVLT
VEGNIGTVQV GNGVTPVEFE AGQDGKPFTI PTKITVGDKV FTVTEVASQA FSYYPDETGR
IVYYPSSITI PSSIKKIQKK GFHGSKAKTI IFDKGSQLEK IEDRAFDFSE LEEIELPASL
EYIGTSAFSF SQKLKKLTFS SSSKLELISH EAFANLSNLE KLTLPKSVKT LGSNLFRLTT
SLKHVDVEEG NESFASVDGV LFSKDKTQLI YYPSQKNDES YKTPKETKEL ASYSFNKNSY
LKKLELNEGL EKIGTFAFAD AIKLEEISLP NSLETIERLA FYGNLELKEL ILPDNVKNFG
KHVMNGLPKL KSLTIGNNIN SLPSFFLSGV LDSLKEIHIK NKSTEFSVKK DTFAIPETVK
FYVTSEHIKD VLKSNLSTSN DIIVEKVDNI KQETDVAKPK KNSNQGVVGW VKDKG
Example 9
Immunization with PcpA .DELTA.SP.DELTA.CBD Elicits Protection
Against Pneumonia in a Sepsis Model
[0119] To determine whether PcpA .DELTA.SP.DELTA.CBD protects
against infection in a murine sepsis model, mice were immunized
with 10, 5, 2.5, 1.25, and 0.625 .mu.g per dose of purified
recombinant PcpA .DELTA.SP.DELTA.CBD (rPcpA .DELTA.SP.DELTA.CBD)
and challenged with approximately 300 CFU of S. pneumoniae strain
WUBM3 per mouse. The rPcpA .DELTA.SP.DELTA.CBD was formulated with
aluminum phosphate adjuvant.
[0120] Briefly, mice were immunized with a PBS adjuvant control, S.
pneumoniae PspA protein containing 30 .mu.g of trivalent
recombinant PspA protein, or 10, 5, 2.5, 1.25, or 0.625 .mu.g per
dose rPcpA .DELTA.SP.DELTA.CBD. Healthy female BALB/c K-72 mice
(Charles River Laboratories, Wilmington, Mass.), approximately 14
per group, were immunized at day 0 subcutaneously (s.c.). A second
immunization was performed at day 21 and a third immunization at
day 43. On day 63, the mice were challenged intraperitoneally (IP)
with a 0.4 ml dose of about 300 CFU of S. pneumoniae strain WU2BM3
bacteria. The percent survival plotted against time (days) is shown
in FIG. 15A. The percent survival at day 7 post challenge is shown
in FIG. 15B.
[0121] These results show that rPcpA is protective from at least
about 0.625 .mu.g per dose to at least about 10 .mu.g per dose. A
statistically significant protection was conferred by rPcpA
compared to the adjuvant control group (Fisher Exact Test 1-sided
or 2-sided).
TABLE-US-00008 TABLE 6 Statistical Analysis of rPcpA Protection
Compared to Control. Stats by Fisher Exact Test PcpA PcpA PcpA PcpA
PcpA SPN222 PBS PspA 10 .mu.g 5 .mu.g 2.5 .mu.g 1.25 .mu.g 0.625
.mu.g % Survival 0 80 67 64 53 60 40 1 sided p value -- 0.000 0.000
0.000 0.001 0.000 0.008 2 sided p value -- 0.000 0.000 0.000 0.002
0.001 0.017
Example 10
Immunization with PcpA .DELTA.SP.DELTA.CBD Elicits Protection
Against Pneumonia
[0122] The rPcpA protein of Example 5 was also used to test the
protective efficacy of this protein against challenge with S.
pneumoniae strain EF3030 in a mouse pneumonia model. Groups of 10
CBA/N mice were immunized subcutaneously with 200 .mu.l of an
immunogen formulation as shown in Table 7, three (3) times at 3
week intervals (day 0, 21 and 42). Three weeks post the 3.sup.rd
immunization (day 63), the mice were challenged, under anesthesia,
intranasally with 5.6.times.10.sup.6 CFUs of strain EF3030. Five
days post challenge (day 68) mice were sacrificed and lung tissue
and blood were harvested and plated for CFU recovery. The
immunization groups were formulated in aluminum phosphate adjuvant
at 3 mg/ml.
TABLE-US-00009 TABLE 7 Immunogen Formulations. Group Immunogen
formulation 1 Placebo (3 mg/mL AlPO.sub.4) 2 Trivalent PspA (50
.mu.g/mL each + 3 mg/mL AlPO.sub.4) 3 PcpA - (100 .mu.g/mL + 3
mg/mL AlPO.sub.4) 4 PcpA - (50 .mu.g/mL + 3 mg/mL AlPO.sub.4) 5
PcpA - (25 .mu.g/mL + 3 mg/mL AlPO.sub.4) 6 PcpA - (12.5 .mu.g/mL +
3 mg/mL AlPO.sub.4) Trivalent PspA immunogen consisted of PspA from
S. pneumoniae Rx1-M1, EF3296 and EF5668.
[0123] The results are shown in FIG. 16. rPcpA protein conferred
significant protection (groups 3-6) when compared to the control
group (Adjuvant alone, group 1) and similar levels of protection to
the positive control (group 2 PspA). The p values from the
Mann-Whitney test are indicated in Table 8.
TABLE-US-00010 TABLE 8 Mann-Whitney Test of rPcpA Protection
Compared to Control. Group 1 Group 2 Group 3 Group 4 Group 5 Group
6 P values 0.0848 0.0407 0.0106 0.0637 0.0087 Mean 3.987 2.360
2.223 1.823 2.375 1.876 Median 3.390 1.590 1.900 1.590 2.590 1.590
Std error 0.6527 0.3397 0.6527 0.2009 0.1819 0.1332
[0124] Publications cited herein and the material for which they
are cited are hereby specifically incorporated by reference in
their entireties.
Sequence CWU 1
1
521192PRTStreptococcus pneumoniae 1Leu Glu Lys Ile Glu Asp Arg Ala
Phe Asp Phe Ser Glu Leu Glu Glu1 5 10 15Ile Glu Leu Pro Ala Ser Leu
Glu Tyr Ile Gly Thr Ser Ala Phe Ser 20 25 30Phe Ser Gln Lys Leu Lys
Lys Leu Thr Phe Ser Ser Ser Ser Lys Leu 35 40 45Glu Leu Ile Ser His
Glu Ala Phe Ala Asn Leu Ser Asn Leu Glu Lys 50 55 60Leu Thr Leu Pro
Lys Ser Val Lys Thr Leu Gly Ser Asn Leu Phe Arg65 70 75 80Leu Thr
Thr Ser Leu Asn Met Leu Met Leu Arg Gly Met Ile Val Ala 85 90 95Ser
Val Asp Gly Val Ser Phe Gln Ser Lys Thr Gln Leu Ile Tyr Tyr 100 105
110Pro Ser Gln Lys Asn Asp Glu Ser Tyr Lys Thr Pro Lys Glu Thr Lys
115 120 125Glu Leu Ala Ser Tyr Ser Phe Asn Lys Asn Ser Tyr Leu Lys
Lys Leu 130 135 140Glu Leu Asn Glu Gly Leu Gln Lys Ile Gly Thr Phe
Ala Phe Ala Asp145 150 155 160Ala Thr Lys Leu Glu Glu Ile Ser Leu
Pro Asn Ser Leu Glu Thr Ile 165 170 175Glu Arg Leu Ala Phe Tyr Gly
Asn Leu Glu Leu Lys Glu Leu Ile Leu 180 185 1902195PRTStreptococcus
pneumoniae 2Leu Glu Lys Ile Glu Asp Arg Ala Phe Asp Phe Ser Glu Leu
Glu Glu1 5 10 15Ile Glu Leu Pro Ala Ser Leu Glu Tyr Ile Gly Thr Ser
Ala Phe Ser 20 25 30Phe Ser Gln Lys Leu Lys Lys Leu Thr Phe Ser Ser
Ser Ser Lys Leu 35 40 45Glu Leu Ile Ser His Glu Ala Phe Ala Asn Leu
Ser Asn Leu Glu Lys 50 55 60Leu Thr Leu Pro Lys Ser Val Lys Thr Leu
Gly Ser Asn Leu Phe Arg65 70 75 80Leu Thr Thr Ser Leu Lys His Val
Asp Val Glu Glu Gly Asn Glu Ser 85 90 95Phe Ala Ser Val Asp Gly Val
Leu Phe Ser Lys Asp Lys Thr Gln Leu 100 105 110Ile Tyr Tyr Pro Ser
Gln Lys Asn Asp Glu Ser Tyr Lys Thr Pro Lys 115 120 125Glu Thr Lys
Glu Leu Ala Ser Tyr Ser Phe Asn Lys Asn Ser Tyr Leu 130 135 140Lys
Lys Leu Glu Leu Asn Glu Gly Leu Glu Lys Ile Gly Thr Phe Ala145 150
155 160Phe Ala Asp Ala Ile Lys Leu Glu Glu Ile Ser Leu Pro Asn Ser
Leu 165 170 175Glu Thr Ile Glu Arg Leu Ala Phe Tyr Gly Asn Leu Glu
Leu Lys Glu 180 185 190Leu Ile Leu 1953379PRTStreptococcus
pneumoniae 3Tyr Val Pro Asn Glu Pro Ile Leu Ala Ala Tyr Val Pro Asn
Glu Pro1 5 10 15Ile Leu Ala Asp Thr Pro Ser Ser Glu Val Ile Lys Glu
Thr Lys Val 20 25 30Gly Ser Ile Ile Gln Gln Asn Asn Ile Lys Tyr Lys
Val Leu Thr Val 35 40 45Glu Gly Asn Ile Gly Thr Val Gln Val Gly Asn
Gly Val Thr Pro Val 50 55 60Glu Phe Glu Ala Gly Gln Asp Gly Lys Pro
Phe Thr Ile Pro Thr Lys65 70 75 80Ile Thr Val Gly Asp Lys Val Phe
Thr Val Thr Glu Val Ala Ser Gln 85 90 95Ala Phe Ser Tyr Tyr Pro Asp
Glu Thr Gly Arg Ile Val Tyr Tyr Pro 100 105 110Ser Ser Ile Thr Ile
Pro Ser Ser Ile Lys Lys Ile Gln Lys Lys Gly 115 120 125Phe His Gly
Ser Lys Ala Lys Thr Ile Ile Phe Asp Lys Gly Ser Gln 130 135 140Leu
Glu Lys Ile Glu Asp Arg Ala Phe Asp Phe Ser Glu Leu Glu Glu145 150
155 160Ile Glu Leu Pro Ala Ser Leu Glu Tyr Ile Gly Thr Ser Ala Phe
Ser 165 170 175Phe Ser Gln Lys Leu Lys Lys Leu Thr Phe Ser Ser Ser
Ser Lys Leu 180 185 190Glu Leu Ile Ser His Glu Ala Phe Ala Asn Leu
Ser Asn Leu Glu Lys 195 200 205Leu Thr Leu Pro Lys Ser Val Lys Thr
Leu Gly Ser Asn Leu Phe Arg 210 215 220Leu Thr Thr Ser Leu Asn Met
Leu Met Leu Arg Gly Met Ile Val Ala225 230 235 240Ser Val Asp Gly
Val Ser Phe Gln Ser Lys Thr Gln Leu Ile Tyr Tyr 245 250 255Pro Ser
Gln Lys Asn Asp Glu Ser Tyr Lys Thr Pro Lys Glu Thr Lys 260 265
270Glu Leu Ala Ser Tyr Ser Phe Asn Lys Asn Ser Tyr Leu Lys Lys Leu
275 280 285Glu Leu Asn Glu Gly Leu Gln Lys Ile Gly Thr Phe Ala Phe
Ala Asp 290 295 300Ala Thr Lys Leu Glu Glu Ile Ser Leu Pro Asn Ser
Leu Glu Thr Ile305 310 315 320Glu Arg Leu Ala Phe Tyr Gly Asn Leu
Glu Leu Lys Glu Leu Ile Leu 325 330 335Pro Asp Asn Val Lys Asn Phe
Gly Lys His Val Met Asn Gly Leu Pro 340 345 350Lys Phe Leu Thr Leu
Ser Gly Asn Asn Ile Asn Ser Leu Pro Ser Phe 355 360 365Phe Leu Ser
Gly Val Leu Asp Ser Leu Lys Glu 370 3754373PRTStreptococcus
pneumoniae 4Tyr Val Pro Asn Glu Pro Ile Leu Ala Asp Thr Pro Ser Ser
Glu Val1 5 10 15Ile Lys Glu Thr Lys Val Gly Ser Ile Ile Gln Gln Asn
Asn Ile Lys 20 25 30Tyr Lys Val Leu Thr Val Glu Gly Asn Ile Gly Thr
Val Gln Val Gly 35 40 45Asn Gly Val Thr Pro Val Glu Phe Glu Ala Gly
Gln Asp Gly Lys Pro 50 55 60Phe Thr Ile Pro Thr Lys Ile Thr Val Gly
Asp Lys Val Phe Thr Val65 70 75 80Thr Glu Val Ala Ser Gln Ala Phe
Ser Tyr Tyr Pro Asp Glu Thr Gly 85 90 95Arg Ile Val Tyr Tyr Pro Ser
Ser Ile Thr Ile Pro Ser Ser Ile Lys 100 105 110Lys Ile Gln Lys Lys
Gly Phe His Gly Ser Lys Ala Lys Thr Ile Ile 115 120 125Phe Asp Lys
Gly Ser Gln Leu Glu Lys Ile Glu Asp Arg Ala Phe Asp 130 135 140Phe
Ser Glu Leu Glu Glu Ile Glu Leu Pro Ala Ser Leu Glu Tyr Ile145 150
155 160Gly Thr Ser Ala Phe Ser Phe Ser Gln Lys Leu Lys Lys Leu Thr
Phe 165 170 175Ser Ser Ser Ser Lys Leu Glu Leu Ile Ser His Glu Ala
Phe Ala Asn 180 185 190Leu Ser Asn Leu Glu Lys Leu Thr Leu Pro Lys
Ser Val Lys Thr Leu 195 200 205Gly Ser Asn Leu Phe Arg Leu Thr Thr
Ser Leu Lys His Val Asp Val 210 215 220Glu Glu Gly Asn Glu Ser Phe
Ala Ser Val Asp Gly Val Leu Phe Ser225 230 235 240Lys Asp Lys Thr
Gln Leu Ile Tyr Tyr Pro Ser Gln Lys Asn Asp Glu 245 250 255Ser Tyr
Lys Thr Pro Lys Glu Thr Lys Glu Leu Ala Ser Tyr Ser Phe 260 265
270Asn Lys Asn Ser Tyr Leu Lys Lys Leu Glu Leu Asn Glu Gly Leu Glu
275 280 285Lys Ile Gly Thr Phe Ala Phe Ala Asp Ala Ile Lys Leu Glu
Glu Ile 290 295 300Ser Leu Pro Asn Ser Leu Glu Thr Ile Glu Arg Leu
Ala Phe Tyr Gly305 310 315 320Asn Leu Glu Leu Lys Glu Leu Ile Leu
Pro Asn Asn Val Lys Asn Phe 325 330 335Gly Lys His Val Met Asn Gly
Leu Pro Lys Leu Lys Ser Leu Thr Ile 340 345 350Gly Asn Asn Ile Asn
Ser Leu Pro Ser Phe Phe Leu Ser Gly Val Leu 355 360 365Asp Ser Leu
Lys Glu 370510PRTStreptococcus pneumoniae 5Leu Glu Lys Ile Glu Asp
Arg Ala Phe Asp1 5 10610PRTStreptococcus pneumoniae 6Phe Ser Glu
Leu Glu Glu Ile Glu Leu Pro1 5 10710PRTStreptococcus pneumoniae
7Ala Ser Leu Glu Tyr Ile Gly Thr Ser Ala1 5 10810PRTStreptococcus
pneumoniae 8Phe Ser Phe Ser Gln Lys Leu Lys Lys Leu1 5
10910PRTStreptococcus pneumoniae 9Thr Phe Ser Ser Ser Ser Lys Leu
Glu Leu1 5 101010PRTStreptococcus pneumoniae 10Ile Ser His Glu Ala
Phe Ala Asn Leu Ser1 5 101110PRTStreptococcus pneumoniae 11Asn Leu
Glu Lys Leu Thr Leu Pro Lys Ser1 5 101210PRTStreptococcus
pneumoniae 12Val Lys Thr Leu Gly Ser Asn Leu Phe Arg1 5
101310PRTStreptococcus pneumoniae 13Leu Thr Thr Ser Leu Asn Met Leu
Met Leu1 5 101410PRTStreptococcus pneumoniae 14Leu Thr Thr Ser Leu
Lys His Val Asp Val1 5 101510PRTStreptococcus pneumoniae 15Arg Gly
Met Ile Val Ala Ser Val Asp Gly1 5 101612PRTStreptococcus
pneumoniae 16Glu Glu Gly Asn Glu Ser Phe Ala Ser Val Asp Gly1 5
101710PRTStreptococcus pneumoniae 17Val Ser Phe Gln Ser Lys Thr Gln
Leu Ile1 5 101811PRTStreptococcus pneumoniae 18Val Leu Phe Ser Lys
Asp Lys Thr Gln Leu Ile1 5 101910PRTStreptococcus pneumoniae 19Tyr
Tyr Pro Ser Gln Lys Asn Asp Glu Ser1 5 102010PRTStreptococcus
pneumoniae 20Tyr Lys Thr Pro Lys Glu Thr Lys Glu Leu1 5
102110PRTStreptococcus pneumoniae 21Ala Ser Tyr Ser Phe Asn Lys Asn
Ser Tyr1 5 102210PRTStreptococcus pneumoniae 22Leu Lys Lys Leu Glu
Leu Asn Glu Gly Leu1 5 102310PRTStreptococcus pneumoniae 23Gln Lys
Ile Gly Thr Phe Ala Phe Ala Asp1 5 102410PRTStreptococcus
pneumoniae 24Glu Lys Ile Gly Thr Phe Ala Phe Ala Asp1 5
102510PRTStreptococcus pneumoniae 25Ala Thr Lys Leu Glu Glu Ile Ser
Leu Pro1 5 102610PRTStreptococcus pneumoniae 26Ala Ile Lys Leu Glu
Glu Ile Ser Leu Pro1 5 102710PRTStreptococcus pneumoniae 27Asn Ser
Leu Glu Thr Ile Glu Arg Leu Ala1 5 102812PRTStreptococcus
pneumoniae 28Phe Tyr Gly Asn Leu Glu Leu Lys Glu Leu Ile Leu1 5
1029122PRTStreptococcus pneumoniae 29Ser Ser Glu Val Ile Lys Glu
Thr Lys Val Gly Ser Ile Ile Gln Gln1 5 10 15Asn Asn Ile Lys Tyr Lys
Val Leu Thr Val Glu Gly Asn Ile Gly Thr 20 25 30Val Gln Val Gly Asn
Gly Val Thr Pro Val Glu Phe Glu Ala Gly Gln 35 40 45Asp Gly Lys Pro
Phe Thr Ile Pro Thr Lys Ile Thr Val Gly Asp Lys 50 55 60Val Phe Thr
Val Thr Glu Val Ala Ser Gln Ala Phe Ser Tyr Tyr Pro65 70 75 80Asp
Glu Thr Gly Arg Ile Val Tyr Tyr Pro Ser Ser Ile Thr Ile Pro 85 90
95Ser Ser Ile Lys Lys Ile Gln Lys Lys Gly Phe His Gly Ser Lys Ala
100 105 110Lys Thr Ile Ile Phe Asp Lys Gly Ser Gln 115
1203043PRTStreptococcus pneumoniae 30Pro Asp Asn Val Lys Asn Phe
Gly Lys His Val Met Asn Gly Leu Pro1 5 10 15Lys Phe Leu Thr Leu Ser
Gly Asn Asn Ile Asn Ser Leu Pro Ser Phe 20 25 30Phe Leu Ser Gly Val
Leu Asp Ser Leu Lys Glu 35 403144PRTStreptococcus pneumoniae 31Pro
Asp Asn Val Lys Asn Phe Gly Lys His Val Met Asn Gly Leu Pro1 5 10
15Lys Leu Lys Ser Leu Thr Ile Gly Asn Asn Ile Asn Ser Leu Pro Ser
20 25 30Phe Phe Leu Ser Gly Val Leu Asp Ser Leu Lys Glu 35
40322127DNAStreptococcus pneumoniae 32atgaaaaaaa ctacaatatt
atcattaact acagctgcgg ttattttagc agcatatgtc 60cctaatgaac caatcctagc
agcatatgtc cctaatgaac caatcctagc agatactcct 120agttcggaag
taatcaaaga gactaaagtt ggaagtatta ttcaacaaaa taatatcaaa
180tataaggttc taactgtaga aggtaacata ggaactgttc aagtgggtaa
tggagttact 240cctgtagagt ttgaagctgg tcaagatgga aaaccattca
cgattcctac aaaaatcaca 300gtaggtgata aagtatttac cgttactgaa
gtagctagtc aagcttttag ttattatcca 360gatgaaacag gtagaattgt
ctactatcct agctctatta ctatcccatc aagcataaaa 420aaaatacaaa
aaaaaggctt ccatggaagt aaagctaaaa ctattatttt tgacaaaggc
480agtcagctgg agaaaattga agatagagct tttgattttt ctgaattaga
agagattgaa 540ttgcctgcat ctctagaata tattggaaca agtgcatttt
cttttagtca aaaattgaaa 600aagctaacct tttcctcaag ttcaaaatta
gaattaatat cacatgaggc ttttgctaat 660ttatcaaatt tagagaaact
aacattacca aaatcggtta aaacattagg aagtaatcta 720tttagactca
ctactagctt aaacatgttg atgttgagag gaatgatcgt tgcctcagtt
780gatggtgttt cgtttcaaag taaaactcaa ttaatttatt atccaagtca
aaaaaatgac 840gaaagttata aaacgcctaa ggagacaaaa gaacttgcat
catattcgtt taataaaaat 900tcttacttga aaaaactcga attgaatgaa
ggtttacaaa aaatcggtac ttttgcattt 960gcggatgcga ccaaacttga
agaaattagc ttaccaaata gtttagaaac tattgaacgt 1020ttagcctttt
acggtaattt agaattaaaa gaacttatat taccagataa tgttaaaaat
1080tttggtaaac acgttatgaa cggtttacca aaatttttaa cattatctgg
taataatatc 1140aactcattgc cgtccttctt cctaagtggc gtcttagatt
cattaaagga aattcatatt 1200aagaataaaa gtacagagtt ttctgtgaaa
aaagatacat ttgcaattcc tgaaactgtt 1260aagttctatg taacatcaga
acatataaaa gatgttctta aatcaaattt atctactagt 1320aatgatatca
ttgttgaaaa agtagataat ataaaacaag aaactgatgt agctaaacct
1380aaaaagaatt ctaatcaggg agtagttggt tgggttaaag acaaaggttt
atggtattac 1440ttaaacgaat caggttcaat ggctactggt tgggttaaag
acaaaggttt atggtattac 1500ttaaacgaat caggttcaat ggctactggt
tgggttaaag acaaaggttt atggtattac 1560ttaaatgaat caggttcaat
ggctactggt tgggttaaag acaaaggctt atggtattac 1620ttaaacgaat
caggttcaat ggctactggt tgggttaaag acaaaggctt atggtattac
1680ttaaacgaat caggttcaat ggctactggt tgggttaaag acaaaggctt
atggtattac 1740ttaaatgaat caggttcaat ggctactggt tgggttaaag
acaaaggctt atggtattac 1800ttaaacgaat caggttcaat ggctactggt
tgggttaaag acaaaggctt atggtattac 1860ttaaatgaat caggttcaat
ggctactggt tgggttaaag acaaaggctt atggtattac 1920ttaaacgaat
caggttcaat ggctactggt tgggttaaag acaaaggctt atggtattac
1980ttaaacgaat caggttcaat ggctactggt tgggttaaag acaaaggctt
atggtattac 2040ttaaatgaat caggttcaat ggctactggt tggtttaaag
tttctggtaa atggtactat 2100acctataatt caggagattt tatttag
2127332106DNAStreptococcus pneumoniae 33atgaaaaaaa ctacaatatt
atcattaact acagctgcgg ttattttagc agatgtccct 60aatgaaccaa tcctagcaga
tactcccagt tcggaagtaa tcaaagagac taaagttgga 120agtattattc
aacaaaataa tatcaaatat aaggttctaa ctgtagaagg taacatagga
180actgttcaag tgggtaatgg agttactcct gtagagtttg aagctggtca
agatggaaaa 240ccattcacga ttcctacaaa aatcacagta ggtgataaag
tatttaccgt tactgaagta 300gctagtcaag cttttagtta ttatccagat
gaaacaggta gaattgtcta ctatcctagc 360tctattacta tcccatcaag
cataaaaaaa atacaaaaaa aaggcttcca tggaagtaaa 420gctaaaacta
ttatttttga caaaggcagt cagctggaga aaattgaaga tagagctttt
480gatttttctg aattagaaga gattgaattg cctgcatctc tagaatatat
tggaacaagt 540gcattttctt ttagtcaaaa attgaaaaag ctaacctttt
cctcaagttc aaaattagaa 600ttaatatcac atgaggcttt tgctaattta
tcaaatttag agaaactaac attaccaaaa 660tcggttaaaa cattaggaag
taatctattt agactcacta ctagcttaaa acatgttgat 720gttgaagaag
gaaatgaatc gtttgcctca gttgatggtg ttttgttttc aaaagataaa
780acccaattaa tttattatcc aagtcaaaaa aatgacgaaa gttataaaac
gcctaaggag 840acaaaagaac ttgcatcata ttcgtttaat aaaaattctt
acttgaaaaa actcgaattg 900aatgaaggtt tagaaaaaat cggtactttt
gcatttgcag atgcgattaa acttgaagaa 960attagcttac caaatagttt
agaaactatt gaacgtttag ccttttacgg taatttagaa 1020ttaaaagaac
ttatattacc aaataatgtt aaaaattttg gtaaacacgt tatgaacggt
1080ttaccaaaat taaaaagttt aacaattggt aataatatca actcattgcc
gtccttcttc 1140ctaagtggcg tcttagattc attaaaggaa attcatatta
agaataaaag tacagagttt 1200tctgtgaaaa aagatacatt tgcaattcct
gaaactgtta agttctatgt aacatcagaa 1260catataaaag atgttcttaa
atcaaattta tctactagta atgatatcat tgttgaaaaa 1320gtagataata
taaaacaaga aactgatgta gctaaaccta aaaagaattc taatcaggga
1380gtagttggtt gggttaaaga caaaggttta tggtattact taaacgaatc
aggttcaatg 1440gctactggtt gggttaaaga caaaggttta tggtattact
taaacgaatc aggttcaatg 1500gctactggtt gggttaaaga caaaggttta
tggtattact taaatgaatc aggttcaatg 1560gctactggtt gggttaaaga
caaaggctta tggtattact taaacgaatc aggttcaatg 1620gctactggtt
gggttaaaga caaaggctta tggtattact taaacgaatc aggttcaatg
1680gctactggtt gggttaaaga caaaggctta tggtattact taaatgaatc
aggttcaatg 1740gctactggtt gggttaaaga caaaggctta tggtattact
taaacgaatc aggttcaatg 1800gctactggtt gggttaaaga caaaggctta
tggtattact taaatgaatc aggttcaatg 1860gctactggtt gggttaaaga
caaaggctta tggtattact taaacgaatc aggttcaatg 1920gctactggtt
gggttaaaga caaaggctta tggtattact taaacgaatc aggttcaatg
1980gctactggtt gggttaaaga caaaggctta tggtattact taaatgaatc
aggttcaatg 2040gctactggtt ggtttaaagt ttctggtaaa tggtactata
cctataattc aggagatttt 2100atttag 210634393DNAStreptococcus
pneumoniae 34ttagagaaac taacattacc aaaatcggtt
aaaacattag gaagtaatct atttagactc 60actactagct taaacatgtt gatgttgaga
ggaatgatcg ttgcctcagt tgatggtgtt 120tcgtttcaaa gtaaaactca
attaatttat tatccaagtc aaaaaaatga cgaaagttat 180aaaacgccta
aggagacaaa agaacttgca tcatattcgt ttaataaaaa ttcttacttg
240aaaaaactcg aattgaatga aggtttacaa aaaatcggta cttttgcatt
tgcggatgcg 300accaaacttg aagaaattag cttaccaaat agtttagaaa
ctattgaacg tttagccttt 360tacggtaatt tagaattaaa agaacttata tta
39335544DNAStreptococcus pneumoniae 35ttagagaaac taacattacc
aaaatcggtt aaaacattag gaagtaatct atttagactc 60actactagct taaaacatgt
tgatgttgaa gaaggaaatg aatcgtttgc ctcagttgat 120ggtgttttgt
tttcaaaaga taaaacccaa ttaatttatt atccaagtca aaaaaatgac
180gaaagttata aaacgcctaa ggagacaaaa gaacttgcat catattcgtt
taataaaaat 240tcttacttga aaaaactcga attgaatgaa ggtttagaaa
aaatcggtac ttttgcattt 300gcagatgcga ttaaacttga agaaattagc
ttaccaaata gtttagaaac tattgaacgt 360ttagcctttt acggtaattt
agaattaaaa gaacttatat taccaaataa tgttaaaaat 420tttggtaaac
acgttatgaa cggtttacca aaattaaaaa gtttaacaat tggtaataat
480atcaactcat tgccgtcctt cttcctaagt ggcgtcttag attcattaaa
ggaaattcat 540atta 544361137DNAStreptococcus pneumoniae
36tatgtcccta atgaaccaat cctagcagca tatgtcccta atgaaccaat cctagcagat
60actcctagtt cggaagtaat caaagagact aaagttggaa gtattattca acaaaataat
120atcaaatata aggttctaac tgtagaaggt aacataggaa ctgttcaagt
gggtaatgga 180gttactcctg tagagtttga agctggtcaa gatggaaaac
cattcacgat tcctacaaaa 240atcacagtag gtgataaagt atttaccgtt
actgaagtag ctagtcaagc ttttagttat 300tatccagatg aaacaggtag
aattgtctac tatcctagct ctattactat cccatcaagc 360ataaaaaaaa
tacaaaaaaa aggcttccat ggaagtaaag ctaaaactat tatttttgac
420aaaggcagtc agctggagaa aattgaagat agagcttttg atttttctga
attagaagag 480attgaattgc ctgcatctct agaatatatt ggaacaagtg
cattttcttt tagtcaaaaa 540ttgaaaaagc taaccttttc ctcaagttca
aaattagaat taatatcaca tgaggctttt 600gctaatttat caaatttaga
gaaactaaca ttaccaaaat cggttaaaac attaggaagt 660aatctattta
gactcactac tagcttaaac atgttgatgt tgagaggaat gatcgttgcc
720tcagttgatg gtgtttcgtt tcaaagtaaa actcaattaa tttattatcc
aagtcaaaaa 780aatgacgaaa gttataaaac gcctaaggag acaaaagaac
ttgcatcata ttcgtttaat 840aaaaattctt acttgaaaaa actcgaattg
aatgaaggtt tacaaaaaat cggtactttt 900gcatttgcgg atgcgaccaa
acttgaagaa attagcttac caaatagttt agaaactatt 960gaacgtttag
ccttttacgg taatttagaa ttaaaagaac ttatattacc agataatgtt
1020aaaaattttg gtaaacacgt tatgaacggt ttaccaaaat ttttaacatt
atctggtaat 1080aatatcaact cattgccgtc cttcttccta agtggcgtct
tagattcatt aaaggaa 1137371119DNAStreptococcus pneumoniae
37gatgtcccta atgaaccaat cctagcagat actcccagtt cggaagtaat caaagagact
60aaagttggaa gtattattca acaaaataat atcaaatata aggttctaac tgtagaaggt
120aacataggaa ctgttcaagt gggtaatgga gttactcctg tagagtttga
agctggtcaa 180gatggaaaac cattcacgat tcctacaaaa atcacagtag
gtgataaagt atttaccgtt 240actgaagtag ctagtcaagc ttttagttat
tatccagatg aaacaggtag aattgtctac 300tatcctagct ctattactat
cccatcaagc ataaaaaaaa tacaaaaaaa aggcttccat 360ggaagtaaag
ctaaaactat tatttttgac aaaggcagtc agctggagaa aattgaagat
420agagcttttg atttttctga attagaagag attgaattgc ctgcatctct
agaatatatt 480ggaacaagtg cattttcttt tagtcaaaaa ttgaaaaagc
taaccttttc ctcaagttca 540aaattagaat taatatcaca tgaggctttt
gctaatttat caaatttaga gaaactaaca 600ttaccaaaat cggttaaaac
attaggaagt aatctattta gactcactac tagcttaaaa 660catgttgatg
ttgaagaagg aaatgaatcg tttgcctcag ttgatggtgt tttgttttca
720aaagataaaa cccaattaat ttattatcca agtcaaaaaa atgacgaaag
ttataaaacg 780cctaaggaga caaaagaact tgcatcatat tcgtttaata
aaaattctta cttgaaaaaa 840ctcgaattga atgaaggttt agaaaaaatc
ggtacttttg catttgcaga tgcgattaaa 900cttgaagaaa ttagcttacc
aaatagttta gaaactattg aacgtttagc cttttacggt 960aatttagaat
taaaagaact tatattacca aataatgtta aaaattttgg taaacacgtt
1020atgaacggtt taccaaaatt aaaaagttta acaattggta ataatatcaa
ctcattgccg 1080tccttcttcc taagtggcgt cttagattca ttaaaggaa
111938366DNAStreptococcus pneumoniae 38agttcggaag taatcaaaga
gactaaagtt ggaagtatta ttcaacaaaa taatatcaaa 60tataaggttc taactgtaga
aggtaacata ggaactgttc aagtgggtaa tggagttact 120cctgtagagt
ttgaagctgg tcaagatgga aaaccattca cgattcctac aaaaatcaca
180gtaggtgata aagtatttac cgttactgaa gtagctagtc aagcttttag
ttattatcca 240gatgaaacag gtagaattgt ctactatcct agctctatta
ctatcccatc aagcataaaa 300aaaatacaaa aaaaaggctt ccatggaagt
aaagctaaaa ctattatttt tgacaaaggc 360agtcag 3663927DNAArtificial
SequenceSynthetically generated oligonucleotide 39cgcggatcca
tatgtcccta atgaacc 274049DNAArtificial SequenceSynthetically
generated oligonucleotide 40gcgctcgagt tcctttaatg aatctaagac
gccacttagg aagaaggac 4941390PRTArtificial SequenceSynthetic
construct 41Met Asp Ile Gly Ile Asn Ser Asp Pro Tyr Val Pro Asn Glu
Pro Ile1 5 10 15Leu Ala Asp Thr Pro Ser Ser Glu Val Ile Lys Glu Thr
Lys Val Gly 20 25 30Ser Ile Ile Gln Gln Asn Asn Ile Lys Tyr Lys Val
Leu Thr Val Glu 35 40 45Gly Asn Ile Gly Thr Val Gln Val Gly Asn Gly
Val Thr Pro Val Glu 50 55 60Phe Glu Ala Gly Gln Asp Gly Lys Pro Phe
Thr Ile Pro Thr Lys Ile65 70 75 80Thr Val Gly Asp Lys Val Phe Thr
Val Thr Glu Val Ala Ser Gln Ala 85 90 95Phe Ser Tyr Tyr Pro Asp Glu
Thr Gly Arg Ile Val Tyr Tyr Pro Ser 100 105 110Ser Ile Thr Ile Pro
Ser Ser Ile Lys Lys Ile Gln Lys Lys Gly Phe 115 120 125His Gly Ser
Lys Ala Lys Thr Ile Ile Phe Asp Lys Gly Ser Gln Leu 130 135 140Glu
Lys Ile Glu Asp Arg Ala Phe Asp Phe Ser Glu Leu Glu Glu Ile145 150
155 160Glu Leu Pro Ala Ser Leu Glu Tyr Ile Gly Thr Ser Ala Phe Ser
Phe 165 170 175Ser Gln Lys Leu Lys Lys Leu Thr Phe Ser Ser Ser Ser
Lys Leu Glu 180 185 190Leu Ile Ser His Glu Ala Phe Ala Asn Leu Ser
Asn Leu Glu Lys Leu 195 200 205Thr Leu Pro Lys Ser Val Lys Thr Leu
Gly Ser Asn Leu Phe Arg Leu 210 215 220Thr Thr Ser Leu Lys His Val
Asp Val Glu Glu Gly Asn Glu Ser Phe225 230 235 240Ala Ser Val Asp
Gly Val Leu Phe Ser Lys Asp Lys Thr Gln Leu Ile 245 250 255Tyr Tyr
Pro Ser Gln Lys Asn Asp Glu Ser Tyr Lys Thr Pro Lys Glu 260 265
270Thr Lys Glu Leu Ala Ser Tyr Ser Phe Asn Lys Asn Ser Tyr Leu Lys
275 280 285Lys Leu Glu Leu Asn Glu Gly Leu Glu Lys Ile Gly Thr Phe
Ala Phe 290 295 300Ala Asp Ala Ile Lys Leu Glu Glu Ile Ser Leu Pro
Asn Ser Leu Glu305 310 315 320Thr Ile Glu Arg Leu Ala Phe Tyr Gly
Asn Leu Glu Leu Lys Glu Leu 325 330 335Ile Leu Pro Asn Asn Val Lys
Asn Phe Gly Lys His Val Met Asn Gly 340 345 350Leu Pro Lys Leu Lys
Ser Leu Thr Ile Gly Asn Asn Ile Asn Ser Leu 355 360 365Pro Ser Phe
Phe Leu Ser Gly Val Leu Asp Ser Leu Lys Glu Leu Glu 370 375 380His
His His His His His385 390421162DNAStreptococcus pneumoniae
42ggatccatat gtccctaatg aaccaatcct agcagcatat gtccctaatg aaccaatcct
60agcagatact cccagttcgg aagtaatcaa agagactaaa gttggaagta ttattcaaca
120aaataatatc aaatataagg ttctaactgt agaaggtaac ataggaactg
ttcaagtggg 180taatggagtt actcctgtag agtttgaagc tggtcaagat
ggaaaaccat tcacgattcc 240tacaaaaatc acagtaggtg ataaagtatt
taccgttact gaagtagcta gtcaagcttt 300tagttattat ccagatgaaa
caggtagaat tgtctactat cctagctcta ttactatccc 360atcaagcata
aaaaaaatac aaaaaaaagg cttccatgga agtaaagcta aaactattat
420ttttgacaaa ggcagtcagc tggagaaaat tgaagataga gcttttgatt
tttctgaatt 480agaagagatt gaattgcctg catctctaga atatattgga
acaagtgcat tttcttttag 540tcaaaaattg aaaaagctaa ccttttcctc
aagttcaaaa ttagaattaa tatcacatga 600ggcttttgct aatttatcaa
atttagagaa actaacatta ccaaaatcgg ttaaaacatt 660aggaagtaat
ctatttagac tcactactag cttaaaacat gttgatgttg aagaaggaaa
720tgaatcgttt gcctcagttg atggtgtttt gttttcaaaa gataaaaccc
aattaattta 780ttatccaagt caaaaaaatg acgaaagtta taaaacgcct
aaggagacaa aagaacttgc 840atcatattcg tttaataaaa attcttactt
gaaaaaactc gaattgaatg aaggtttaga 900aaaaatcggt acttttgcat
ttgcagatgc gattaaactt gaagaaatta gcttaccaaa 960tagtttagaa
actattgaac gtttagcctt ttacggtaat ttagaattaa aagaacttat
1020attaccaaat aatgttaaaa attttggtaa acacgttatg aacggtttac
caaaattaaa 1080aagtttaaca attggtaata atatcaactc attgccgtcc
ttcttcctaa gtggcgtctt 1140agattcatta aaggaactcg ag
11624351DNAArtificial SequencePrimer 43tagcctcgag ttaacctttg
tctttaaccc aaccaactac tccctgatta g 514444DNAArtificial
SequencePrimer 44ctaatgaacc acatatggca gatactccta gttcggaagt aatc
4445445PRTStreptococcus pneumoniae serotype 6 45Met Ala Asp Thr Pro
Ser Ser Glu Val Ile Lys Glu Thr Lys Val Gly1 5 10 15Ser Ile Ile Gln
Gln Asn Asn Ile Lys Tyr Lys Val Leu Thr Val Glu 20 25 30Gly Asn Ile
Gly Thr Val Gln Val Gly Asn Gly Val Thr Pro Val Glu 35 40 45Phe Glu
Ala Gly Gln Asp Gly Lys Pro Phe Thr Ile Pro Thr Lys Ile 50 55 60Thr
Val Gly Asp Lys Val Phe Thr Val Thr Glu Val Ala Ser Gln Ala65 70 75
80Phe Ser Tyr Tyr Pro Asp Glu Thr Gly Arg Ile Val Tyr Tyr Pro Ser85
90 95Ser Ile Thr Ile Pro Ser Ser Ile Lys Lys Ile Gln Lys Lys Gly
Phe 100 105 110His Gly Ser Lys Ala Lys Thr Ile Ile Phe Asp Lys Gly
Ser Gln Leu 115 120 125Glu Lys Ile Glu Asp Arg Ala Phe Asp Phe Ser
Glu Leu Glu Glu Ile 130 135 140Glu Leu Pro Ala Ser Leu Glu Tyr Ile
Gly Thr Ser Ala Phe Ser Phe145 150 155 160Ser Gln Lys Leu Lys Lys
Leu Thr Phe Ser Ser Ser Ser Lys Leu Glu 165 170 175Leu Ile Ser His
Glu Ala Phe Ala Asn Leu Ser Asn Leu Glu Lys Leu 180 185 190Thr Leu
Pro Lys Ser Val Lys Thr Leu Gly Ser Asn Leu Phe Arg Leu 195 200
205Thr Thr Ser Leu Lys His Val Asp Val Glu Glu Gly Asn Glu Ser Phe
210 215 220Ala Ser Val Asp Gly Val Leu Phe Ser Lys Asp Lys Thr Gln
Leu Ile225 230 235 240Tyr Tyr Pro Ser Gln Lys Asn Asp Glu Ser Tyr
Lys Thr Pro Lys Glu 245 250 255Thr Lys Glu Leu Ala Ser Tyr Ser Phe
Asn Lys Asn Ser Tyr Leu Lys 260 265 270Lys Leu Glu Leu Asn Glu Gly
Leu Glu Lys Ile Gly Thr Phe Ala Phe 275 280 285Ala Asp Ala Ile Lys
Leu Glu Glu Ile Ser Leu Pro Asn Ser Leu Glu 290 295 300Thr Ile Glu
Arg Leu Ala Phe Tyr Gly Asn Leu Glu Leu Lys Glu Leu305 310 315
320Ile Leu Pro Asp Asn Val Lys Asn Phe Gly Lys His Val Met Asn Gly
325 330 335Leu Pro Lys Leu Lys Ser Leu Thr Ile Gly Asn Asn Ile Asn
Ser Leu 340 345 350Pro Ser Phe Phe Leu Ser Gly Val Leu Asp Ser Leu
Lys Glu Ile His 355 360 365Ile Lys Asn Lys Ser Thr Glu Phe Ser Val
Lys Lys Asp Thr Phe Ala 370 375 380Ile Pro Glu Thr Val Lys Phe Tyr
Val Thr Ser Glu His Ile Lys Asp385 390 395 400Val Leu Lys Ser Asn
Leu Ser Thr Ser Asn Asp Ile Ile Val Glu Lys 405 410 415Val Asp Asn
Ile Lys Gln Glu Thr Asp Val Ala Lys Pro Lys Lys Asn 420 425 430Ser
Asn Gln Gly Val Val Gly Trp Val Lys Asp Lys Gly 435 440
445461338DNAStreptococcus pneumoniae serotype 6 46atggcagata
ctcctagttc ggaagtaatc aaagagacta aagttggaag tattattcaa 60caaaataata
tcaaatataa ggttctaact gtagaaggta acataggaac tgttcaagtg
120ggtaatggag ttactcctgt agagtttgaa gctggtcaag atggaaaacc
attcacgatt 180cctacaaaaa tcacagtagg tgataaagta tttaccgtta
ctgaagtagc tagtcaagct 240tttagttatt atccagatga aacaggtaga
attgtctact atcctagctc tattactatc 300ccatcaagca taaaaaaaat
acaaaaaaaa ggcttccatg gaagtaaagc taaaactatt 360atttttgaca
aaggcagtca gctggagaaa attgaagata gagcttttga tttttctgaa
420ttagaagaga ttgaattgcc tgcatctcta gaatatattg gaacaagtgc
attttctttt 480agtcaaaaat tgaaaaagct aaccttttcc tcaagttcaa
aattagaatt aatatcacat 540gaggcttttg ctaatttatc aaatttagag
aaactaacat taccaaaatc ggttaaaaca 600ttaggaagta atctatttag
actcactact agcttaaaac atgttgatgt tgaagaagga 660aatgaatcgt
ttgcctcagt tgatggtgtt ttgttttcaa aagataaaac tcaattaatt
720tattatccaa gtcaaaaaaa tgacgaaagt tataaaacgc ctaaggagac
aaaagaactt 780gcatcatatt cgtttaataa aaattcttac ttgaaaaaac
tcgaattgaa tgaaggttta 840gaaaaaatcg gtacttttgc atttgcggat
gcgattaaac ttgaagaaat tagcttacca 900aatagtttag aaactattga
acgtttagcc ttttacggta atttagaatt aaaagaactt 960atattaccag
ataatgttaa aaattttggt aaacacgtta tgaacggttt accaaaatta
1020aaaagtttaa caattggtaa taatatcaac tcattgccgt ccttcttcct
aagtggcgtc 1080ttagattcat taaaggaaat tcatattaag aataaaagta
cagagttttc tgtgaaaaaa 1140gatacatttg caattcctga aactgttaag
ttctatgtaa catcagaaca tataaaagat 1200gttcttaaat caaatttatc
tactagtaat gatatcattg ttgaaaaagt agataatata 1260aaacaagaaa
ctgatgtagc taaacctaaa aagaattcta atcagggagt agttggttgg
1320gttaaagaca aaggttaa 1338471926DNAStreptococcus pneumoniae
47atgaaaaaaa ctacaatatt atcattaact acagctgcgg ttattttagc agcatatgtc
60cctaatgaac caatcctagc agatactcct agttcggaag taatcaaaga gactaaagtt
120ggaagtatta ttcaacaaaa taatatcaaa tataaggttc taactgtaga
aggtaacata 180ggaactgttc aagtgggtaa tggagttact cctgtagagt
ttgaagctgg tcaagatgga 240aaaccattca cgattcctac aaaaatcaca
gtaggtgata aagtatttac cgttactgaa 300gtagctagtc aagcttttag
ttattatcca gatgaaacag gtagaattgt ctactatcct 360agctctatta
ctatcccatc aagcataaaa aaaatacaaa aaaaaggctt ccatggaagt
420aaagctaaaa ctattatttt tgacaaaggc agtcagctgg agaaaattga
agatagagct 480tttgattttt ctgaattaga agagattgaa ttgcctgcat
ctctagaata tattggaaca 540agtgcatttt cttttagtca aaaattgaaa
aagctaacct tttcctcaag ttcaaaatta 600gaattaatat cacatgaggc
ttttgctaat ttatcaaatt tagagaaact aacattacca 660aaatcggtta
aaacattagg aagtaatcta tttagactca ctactagctt aaaacatgtt
720gatgttgaag aaggaaatga atcgtttgcc tcagttgatg gtgttttgtt
ttcaaaagat 780aaaactcaat taatttatta tccaagtcaa aaaaatgacg
aaagttataa aacgcctaag 840gagacaaaag aacttgcatc atattcgttt
aataaaaatt cttacttgaa aaaactcgaa 900ttgaatgaag gtttagaaaa
aatcggtact tttgcatttg cggatgcgat taaacttgaa 960gaaattagct
taccaaatag tttagaaact attgaacgtt tagcctttta cggtaattta
1020gaattaaaag aacttatatt accagataat gttaaaaatt ttggtaaaca
cgttatgaac 1080ggtttaccaa aattaaaaag tttaacaatt ggtaataata
tcaactcatt gccgtccttc 1140ttcctaagtg gcgtcttaga ttcattaaag
gaaattcata ttaagaataa aagtacagag 1200ttttctgtga aaaaagatac
atttgcaatt cctgaaactg ttaagttcta tgtaacatca 1260gaacatataa
aagatgttct taaatcaaat ttatctacta gtaatgatat cattgttgaa
1320aaagtagata atataaaaca agaaactgat gtagctaaac ctaaaaagaa
ttctaatcag 1380ggagtagttg gttgggttaa agacaaaggt ttatggtatt
acttaaacga atcaggttca 1440atggctactg gttgggttaa agacaaaggt
ttatggtatt acttaaacga atcaggttca 1500atggctactg gttgggttaa
agacaaaggc ttatggtatt acttaaacga atcaggttca 1560atggctactg
gttgggttaa agacaaaggc ttatggtatt acttaaatga atcaggttca
1620atggctactg gttgggttaa agacaaaggc ttatggtatt acttaaacga
atcaggttca 1680atggctactg gttgggttaa agacaaaggc ttatggtatt
acttaaacga atcaggttca 1740atggctactg gttgggttaa agacaaaggc
ttatggtatt acttaaatga atcaggttca 1800atggctactg gttggtttac
agtttctggt aaatggtact atacctataa ttcaggagat 1860ttattagtaa
acacgactac acccgatggc tatcgagtca atgctaacgg tgagtgggta 1920ggataa
19264821DNAArtificial SequencePrimer 48aactgttcaa gtgggtaatg g
214922DNAArtificial SequencePrimer 49tgaacttgag gaaaaggtta gc
225038DNAArtificial SequencePrimer 50atgaaaaaac tacaatatta
tcattaacta cagctgcg 385133DNAArtificial SequencePrimer 51ccataaacct
ttgtctttaa cccaaccaac tac 3352311PRTStreptococcus pneumoniae 52Ile
His Ile Lys Asn Lys Ser Thr Glu Phe Ser Val Lys Lys Asp Thr1 5 10
15Phe Ala Ile Pro Glu Thr Val Lys Phe Tyr Val Thr Ser Glu His Ile
20 25 30Lys Asp Val Leu Lys Ser Asn Leu Ser Thr Ser Asn Asp Ile Ile
Val 35 40 45Glu Lys Val Asp Asn Ile Lys Gln Glu Thr Asp Val Ala Lys
Pro Lys 50 55 60Lys Asn Ser Asn Gln Gly Val Val Gly Trp Val Lys Asp
Lys Gly Leu65 70 75 80Trp Tyr Tyr Leu Asn Glu Ser Gly Ser Met Ala
Thr Gly Trp Val Lys 85 90 95Asp Lys Gly Leu Trp Tyr
Tyr Leu Asn Glu Ser Gly Ser Met Ala Thr 100 105 110Gly Trp Val Lys
Asp Lys Gly Leu Trp Tyr Tyr Leu Asn Glu Ser Gly 115 120 125Ser Met
Ala Thr Gly Trp Val Lys Asp Lys Gly Leu Trp Tyr Tyr Leu 130 135
140Asn Glu Ser Gly Ser Met Ala Thr Gly Trp Val Lys Asp Lys Gly
Leu145 150 155 160Trp Tyr Tyr Leu Asn Glu Ser Gly Ser Met Ala Thr
Gly Trp Val Lys 165 170 175Asp Lys Gly Leu Trp Tyr Tyr Leu Asn Glu
Ser Gly Ser Met Ala Thr 180 185 190Gly Trp Val Lys Asp Lys Gly Leu
Trp Tyr Tyr Leu Asn Glu Ser Gly 195 200 205Ser Met Ala Thr Gly Trp
Val Lys Asp Lys Gly Leu Trp Tyr Tyr Leu 210 215 220Asn Glu Ser Gly
Ser Met Ala Thr Gly Trp Val Lys Asp Lys Gly Leu225 230 235 240Trp
Tyr Tyr Leu Asn Glu Ser Gly Ser Met Ala Thr Gly Trp Val Lys 245 250
255Asp Lys Gly Leu Trp Tyr Tyr Leu Asn Glu Ser Gly Ser Met Ala Thr
260 265 270Gly Trp Val Lys Asp Lys Gly Leu Trp Tyr Tyr Leu Asn Glu
Ser Gly 275 280 285Ser Met Ala Thr Gly Trp Phe Lys Val Ser Gly Lys
Trp Tyr Tyr Thr 290 295 300Tyr Asn Ser Gly Asp Phe Ile305 310
* * * * *
References